<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ciprofloxacin (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ciprofloxacin (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ciprofloxacin (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11594" href="/d/html/11594.html" rel="external">see "Ciprofloxacin (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="15951" href="/d/html/15951.html" rel="external">see "Ciprofloxacin (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F9611220"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious adverse reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including: tendinopathy and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ciprofloxacin immediately and avoid the use of fluoroquinolones in patients who experience any of these serious adverse reactions. Because fluoroquinolones have been associated with serious adverse reactions, reserve ciprofloxacin for use in patients who have no alternative treatment options for the following indications: acute exacerbation of chronic bronchitis, acute sinusitis, and acute uncomplicated cystitis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Exacerbation of myasthenia gravis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid ciprofloxacin in patients with known history of myasthenia gravis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9611233"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cipro</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868809"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Ciprofloxacin;</li>
<li>AG-Ciprofloxacin;</li>
<li>APO-Ciproflox;</li>
<li>Auro-Ciprofloxacin;</li>
<li>BIO-Ciprofloxacin;</li>
<li>Cipro;</li>
<li>Cipro XL [DSC];</li>
<li>DOM-Ciprofloxacin [DSC];</li>
<li>GEN-Ciprofloxacin;</li>
<li>GMD-Ciprofloxacin;</li>
<li>JAMP-Ciprofloxacin;</li>
<li>Mar-Ciprofloxacin;</li>
<li>MINT-Ciproflox;</li>
<li>NRA-Ciprofloxacin;</li>
<li>PMS-Ciprofloxacin;</li>
<li>PMS-Ciprofloxacin XL;</li>
<li>Priva-Ciprofloxacin [DSC];</li>
<li>PRO-Ciprofloxacin;</li>
<li>RATIO-Ciprofloxacin;</li>
<li>RIVA-Ciprofloxacin;</li>
<li>SANDOZ Ciprofloxacin;</li>
<li>TARO-Ciproflox;</li>
<li>TARO-Ciprofloxacin [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9660646"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Fluoroquinolone</li></ul></div>
<div class="block doa drugH1Div" id="F9611424"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax:</b>
<b> Note:</b> Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inhalational (postexposure prophylaxis):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 500 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 400 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy: Duration depends on anthrax vaccine status and series completion, age, immune status, and pregnancy/breastfeeding status. For those who have not previously received an anthrax vaccine, duration ranges from 42 to 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>). Some experts favor longer durations of prophylaxis (eg, total of 3 to 4 months) for patients who are immunocompromised or remain unvaccinated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wilson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wilson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Anthrax vaccine should also be administered to exposed individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous (without systemic involvement), treatment (off-label use):</i>
<b>Oral:</b> Immediate release: 500 mg every 12 hours for 7 to 10 days after naturally acquired infection; 60 days following biological weapon-related event. <b>Note:</b> Treat patients with extensive edema or cutaneous lesions of the head or neck with a parenteral regimen recommended for systemic involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic (with or without meningitis), treatment (off-label use): </i>
<b>IV:</b> 400 mg every 8 hours, in combination with other appropriate agents for ≥2 to 3 weeks or until clinically stable, whichever is longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Antitoxin should also be administered for systemic anthrax. Following the course of IV combination therapy for systemic anthrax infection (including meningitis), patients exposed to aerosolized spores require oral monotherapy to complete a total antimicrobial course of 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb1f0aaf-41ff-4651-ad53-d81e2f072c7d">Bite wound infection, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, prophylaxis or treatment (animal and human bites) (alternative agent) (off-label use): Note:</b> Use in combination with an appropriate agent for anaerobes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 to 750 mg twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 400 mg every 12 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Duration of therapy: 3 to 5 days for prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>); duration of treatment for established infection is typically 5 to 14 days and varies based on patient-specific factors, including clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.1','lexi-content-ref-Baddour.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.1','lexi-content-ref-Baddour.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a63ad5fc-e17e-4a1b-916a-463aa388096b">Cat scratch disease, lymphadenitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cat scratch disease, lymphadenitis (nondisseminated) (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Some experts reserve use for patients who are immunocompetent and are unable to receive other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 mg twice daily for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1999905','lexi-content-ref-Spach.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1999905','lexi-content-ref-Spach.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e2a56fe-ae38-44c3-9cbe-f0cf191e8b37">Chancroid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chancroid (alternative agent) (off-label use): Oral:</b> Immediate release: 500 mg twice daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Hicks.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Hicks.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2fc48950-b56f-4f0c-9207-d09e668a6f6b">Cholera</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholera (<i>Vibrio cholerae</i>) (alternative agent) (off-label use): Oral:</b> Immediate release: 1 g as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11170940','lexi-content-ref-8709688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11170940','lexi-content-ref-8709688'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation (off-label use): Note: </b>Some experts reserve for patients with risk factors for poor outcomes (eg, ≥65 years of age, FEV<sub>1</sub> &lt;50% predicted, frequent exacerbations, significant comorbidities) who are at risk of <i>Pseudomonas</i> infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sethi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sethi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 to 750 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20536364','lexi-content-ref-10435684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20536364','lexi-content-ref-10435684'])">Ref</a></span>) for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3e7cb1f0-5fda-4c4b-8f19-13c9af2a56bb">Crohn disease, treatment of simple perianal fistulas, adjunctive agent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease, treatment of simple perianal fistulas, adjunctive agent (off-label use):</b>
<b>Oral:</b> Immediate release: 500 mg twice daily, with or without metronidazole, for 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508','lexi-content-ref-34051983','lexi-content-ref-Bitton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508','lexi-content-ref-34051983','lexi-content-ref-Bitton.1'])">Ref</a></span>); some experts recommend treatment duration up to 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c82d3ece-50d0-49c2-ae32-3a2c16f1d66e">Diabetic foot infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection (off-label use): Note:</b> When used as empiric therapy, ciprofloxacin should be used in combination with other appropriate agents.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate infection: <b>Oral:</b> Immediate release: 500 mg every 12 hours (750 mg every 12 hours if <i>Pseudomonas</i>
<i>aeruginosa</i> is suspected) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe infection: <b>IV:</b> 400 mg every 12 hours (400 mg every 8 hours if <i>P. aeruginosa</i> is suspected) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HACEK organisms (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 500 mg every 12 hours for 4 weeks (native valve) or 6 weeks (prosthetic valve) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 400 mg every 12 hours for 4 weeks (native valve) or 6 weeks (prosthetic valve) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>S. aureus, methicillin-susceptible, oral step-down therapy for patients who inject drugs: </i>
<b>Note:</b> Not first-line therapy; data are limited. Reserve use for patients who inject drugs who had initial clinical improvement with IV treatment but cannot complete IV standard of care therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414','lexi-content-ref-8686718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414','lexi-content-ref-8686718'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 750 mg every 12 hours in combination with rifampin for a total duration, including initial IV therapy, of 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414','lexi-content-ref-8686718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414','lexi-content-ref-8686718'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9474c76-c81a-48ef-b80f-72ce1a0e25f5">Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Empiric oral regimens may be appropriate for patients with mild to moderate infection. Other patients may be switched from IV to oral therapy when clinically improved and able to tolerate an oral diet (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholecystitis, acute:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>The addition of anaerobic therapy (eg, metronidazole) is recommended if biliary-enteric anastomosis is present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 400 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">or</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 500 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration:</b> Continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other intra-abdominal infections (eg, appendicitis, diverticulitis, intra-abdominal abscess): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For acute diverticulitis, some experts suggest deferring antibiotics in otherwise healthy immunocompetent patients with mild disease; however, data on this approach in outpatients are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26453777','lexi-content-ref-30664553','lexi-content-ref-28719679','lexi-content-ref-28085573','lexi-content-ref-32073652']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26453777','lexi-content-ref-30664553','lexi-content-ref-28719679','lexi-content-ref-28085573','lexi-content-ref-32073652'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 400 mg every 12 hours in combination with metronidazole.</p>
<p style="text-indent:-2em;margin-left:6em;">or</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 500 mg every 12 hours in combination with metronidazole.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration:</b> Total duration of therapy (which may include transition to oral antibiotics) is for 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial (community-acquired or health care-associated) (alternative agent) (off-label use):</b>
<b>IV:</b> 400 mg every 8 to 12 hours; for empiric therapy, must be used in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c81ebc18-f3e1-446c-bf53-487572248cdb">Meningococcal meningitis prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal meningitis prophylaxis (off-label use):</b>
<b>Oral:</b> Immediate release: 500 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23515099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23515099'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="386921fa-07a3-493e-a6cb-8d72fb9ffb37">Neutropenia, antibacterial prophylaxis in high-risk patients anticipated to have an ANC ≤100 cells/mm<sup>3</sup> for &gt;7 days</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia (chemotherapy-induced), antibacterial prophylaxis in high-risk patients anticipated to have an ANC ≤100 cells/mm<sup>3</sup> for &gt;7 days</b>
<b>(off-label use):</b>
<b>Oral:</b> Immediate release: 500 to 750 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10423464','lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10423464','lexi-content-ref-Wingard.1'])">Ref</a></span>); some clinicians will provide antibacterial prophylaxis if ANC is anticipated to be &lt;500 cells/mm<sup>3</sup> for &gt;7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wingard.1'])">Ref</a></span>). For hematopoietic cell transplant recipients, begin at the time of stem cell infusion and continue until recovery of neutropenia or until initiation of empiric antibiotic therapy for neutropenic fever (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42a786df-77b0-4176-9054-cd5fea8a9f13">Neutropenic fever, low-risk cancer patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, low-risk cancer patients (empiric therapy) (off-label use):</b>
<b>Oral:</b> Immediate release: 750 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10423465','lexi-content-ref-23358983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10423465','lexi-content-ref-23358983'])">Ref</a></span>) in combination with amoxicillin and clavulanate; continue until fever and neutropenia have resolved.<b> Note</b>: Avoid in patients who have received fluoroquinolone prophylaxis. Administer first dose in the health care setting (after blood cultures are drawn); observe patient for ≥4 hours before discharge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29461916','lexi-content-ref-10423464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29461916','lexi-content-ref-10423464'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9d9ff41-d96a-4eb8-b9f5-e76594705fc3">Osteomyelitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Treatment: Immediate release: 500 to 750 mg every 12 hours; when treating <i>P. aeruginosa</i>, 750 mg every 12 hours for ≥6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16297731','lexi-content-ref-26229122','lexi-content-ref-Osmon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16297731','lexi-content-ref-26229122','lexi-content-ref-Osmon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic suppression in presence of retained infected orthopedic hardware: Immediate release: 250 to 500 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 400 mg every 12 hours; when treating <i>P. aeruginosa</i>, 400 mg every 8 hours for ≥6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16297731','lexi-content-ref-26229122','lexi-content-ref-Osmon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16297731','lexi-content-ref-26229122','lexi-content-ref-Osmon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cef46916-6e8d-4432-9061-e9a4345c59d2">Peritoneal dialysis catheter, exit-site or tunnel infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis catheter, exit-site or tunnel infection (off-label use):</b>
<b>Oral:</b> Immediate release: 250 mg twice daily. When used for empiric therapy, must be used in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28360365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28360365'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d4cf660-fc6c-4182-9e8b-10ee80fcb30b">Plague</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague (<i>Yersinia pestis</i>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postexposure prophylaxis:</i>
<b>Oral:</b> Immediate release: 500 to 750 mg every 12 hours (for patients who are pregnant, 500 mg every 8 hours or 750 mg every 12 hours) for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment, excluding meningitis:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Immediate release: 750 mg every 12 hours; for patients who are pregnant, 500 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 400 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Duration of therapy: 7 to 14 days and for at least a few days after clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Stout.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Stout.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26be3532-b981-44af-8da0-9f4e2ad4a0b7">Pneumonia, as a component of empiric therapy or pathogen-specific therapy for <i>P. aeruginosa</i> in hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, as a component of empiric therapy or pathogen-specific therapy for </b>
<i>
<b>P. aeruginosa </b></i>
<b>in hospitalized patients</b>
<b>: Note:</b> For empiric therapy, use in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 750 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12749509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12749509'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 400 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Duration of therapy: Varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3488d7c-e7b9-412e-a573-cbcc83f5f171">Pouchitis, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pouchitis (post–ileal pouch-anal anastomosis), acute (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial therapy: <b>Oral:</b> Immediate release: 500 mg every 12 hours for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19817675','lexi-content-ref-31785173','lexi-content-ref-11720319','lexi-content-ref-Shen.2020','lexi-content-ref-21775695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19817675','lexi-content-ref-31785173','lexi-content-ref-11720319','lexi-content-ref-Shen.2020','lexi-content-ref-21775695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Refractory disease: <b>Oral:</b> Immediate release: 500 mg every 12 hours for 28 days as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31333137','lexi-content-ref-Shen.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31333137','lexi-content-ref-Shen.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fd32e36-aea8-4922-9fc3-8f98fc89d1d8">Prostatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostatitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acute bacterial prostatitis (off-label use): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 500 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy: 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.1','lexi-content-ref-24223408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.1','lexi-content-ref-24223408'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Chronic bacterial prostatitis:</i></b>
<b>Oral:</b> Immediate release: 500 mg every 12 hours for 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection (off-label use): Note: </b>Alternative agent for certain pathogens.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Gram-negative bacilli:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Immediate release: 750 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>); some experts prefer 400 mg every 8 hours for infections caused by <i>P. aeruginosa</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Staphylococcus aureus</i>, oral continuation therapy (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Immediate release: 500 to 750 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16153261','lexi-content-ref-9605897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16153261','lexi-content-ref-9605897'])">Ref</a></span>) in combination with rifampin; total treatment duration is a minimum of 3 months, depending on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic suppressive therapy for P. aeruginosa: </i>
<b>Oral:</b> Immediate release: 250 to 500 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25833927','lexi-content-ref-26785402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25833927','lexi-content-ref-26785402'])">Ref</a></span>). Given <i>S. pneumoniae</i> resistance, ciprofloxacin is not recommended for the empiric treatment of acute bacterial rhinosinusitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25833927','lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25833927','lexi-content-ref-22438350'])">Ref</a></span>). Additionally, the FDA recommends ciprofloxacin be reserved for patients who have no alternative treatment options in the treatment of acute rhinosinusitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 mg twice daily (manufacturer’s labeling); typical duration is 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25833927','lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25833927','lexi-content-ref-22438350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); typical duration is 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25833927','lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25833927','lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7f7038e-52b0-4f90-8adf-95b75d44fa65">
<i>Salmonella</i> species, GI infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Salmonella</i> species, GI infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nontyphoidal, severe (nonbacteremic) illness or any severity in patients at high risk for invasive disease:</i>
<b>Oral:</b> Immediate release: 500 mg twice daily for 3 to 14 days (7 to 14 days in patients with HIV with a CD4 count ≥200 cells/mm<sup>3</sup>). <b>Note:</b> Immunosuppressed patients (eg, patients with HIV and CD4 count &lt;200 cells/mm<sup>3</sup>) require a longer duration of treatment (eg, weeks to months) and may require a higher dose (eg, 750 mg twice daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-Hohmann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-Hohmann.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nontyphoidal bloodstream infection:</i>
<b>IV:</b> 400 mg twice daily for 14 days. <b>Note:</b> Immunosuppressed patients (eg, patients with HIV with CD4 count &lt;200 cells/mm<sup>3</sup>) and those with an extraintestinal focus of infection require a longer duration of treatment (eg, weeks or months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-Hohmann.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-Hohmann.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Typhoid fever (Salmonella typhi and paratyphi):</i> Severe disease or mild to moderate infection in patients at high risk of developing invasive disease. <b>Note:</b> Use only if MIC ≤0.06 mcg/mL as the incidence of fluoroquinolone-resistant strains is increasing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22752519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22752519'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 500 mg every 12 hours for 7 to 10 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 400 mg every 12 hours for 7 to 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9357c8a8-bc61-4588-803a-17d7cba42c78">Septic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic arthritis (alternative agent): Note:</b> Use in combination with a second anti-pseudomonal agent for initial treatment in patients with increased risk for mortality or resistant pathogens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 750 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 400 mg every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Duration of therapy: 3 to 4 weeks (in the absence of osteomyelitis), including oral step-down therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc511cf9-80be-4243-a139-df398f0bd937">
<i>Shigella</i> GI infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Shigella</i> GI infection (off-label dose):</b>
<b>Note: </b>Use only if MIC is &lt; 0.12 mcg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 mg twice daily or 750 mg once daily for 3 days; the duration should be extended to 5 to 7 days for those with <i>S. dysenteriae</i> type 1 infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Agha.1','lexi-content-ref-11170940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Agha.1','lexi-content-ref-11170940'])">Ref</a></span>). <b>Note:</b> Patients with HIV require a longer duration of treatment (eg, 5 to 7 days) and may require a higher dose (eg, 750 mg twice daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Agha.1','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Agha.1','lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Surgical site incisional infection (eg, intestinal or GU tract, perineum, or axilla):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 750 mg every 12 hours in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 400 mg every 12 hours in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0ae1fc5-2f2e-4d8b-98f2-20932ab0eea9">Spontaneous bacterial peritonitis, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spontaneous bacterial peritonitis, prophylaxis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For secondary prophylaxis in patients with prior spontaneous bacterial peritonitis (SBP) and primary prophylaxis in patients at high risk for SBP (eg, low ascites protein [&lt;1.5 g/dL] with advanced liver failure or impaired kidney function). Some experts also use for prophylaxis during hospitalization in patients with cirrhosis and either acute GI bleeding or ascites protein &lt;1 g/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-Runyon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-Runyon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342'])">Ref</a></span>). For patients with cirrhosis and acute GI bleeding, some experts use 500 mg twice daily following, or as an alternative to, parenteral prophylaxis, for a total antibiotic duration of 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Runyon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Runyon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (off-label use): Note:</b> Use in combination with other appropriate agents may be warranted (procedure-dependent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (alternative agent):</b> 400 mg within 120 minutes prior to surgical incision (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 mg within 120 minutes prior to surgical incision. <b>Note:</b> Reserve use for high-risk cystoscopy (eg, urine culture positive, preoperative catheter, or placement of prosthetic material), cystoscopy with manipulation (eg, transrectal prostate biopsy), or upper GU tract instrumentation. Due to increasing resistance among urinary pathogens, review local sensitivity prior to use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Anderson.1','lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Anderson.1','lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf64d97c-215c-415e-9c7b-86a9dd06850a">Tularemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tularemia (<i>Francisella tularensis</i>) (off-label use): </b>
<b>Note:</b> Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild disease:</i>
<b>Oral:</b> Immediate release: 500 or 750 mg twice daily for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15677845','lexi-content-ref-11386933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15677845','lexi-content-ref-11386933'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis:</i>
<b>Oral:</b> Immediate release: 500 or 750 mg twice daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15677845','lexi-content-ref-11386933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15677845','lexi-content-ref-11386933'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection) (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use is discouraged due to safety concerns and increasing resistance; reserve for those who have no alternative treatment options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564','lexi-content-ref-FDA.2','lexi-content-ref-Hooton.2','lexi-content-ref-Hooton.3','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564','lexi-content-ref-FDA.2','lexi-content-ref-Hooton.2','lexi-content-ref-Hooton.3','lexi-content-ref-21292654'])">Ref</a></span>). However, for men who have severe symptoms or there is concern for early prostate involvement, some experts prefer fluoroquinolones (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 250 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22318279','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22318279','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Extended release [Canadian product]: 500 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: 3 days (females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22318279','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22318279','lexi-content-ref-21292654'])">Ref</a></span>) or 5 days (males) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, complicated (including pyelonephritis):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If the prevalence of fluoroquinolone resistance is &gt;10%, an initial dose of a long-acting parenteral antimicrobial (eg, ceftriaxone) followed by oral therapy is recommended for outpatients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.1','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.1','lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 500 mg every 12 hours for 5 to 7 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Extended release [Canadian product]: 1 g every 24 hours for 5 to 7 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b> (inpatient): 400 mg every 12 hours for a total of 5 to 7 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Missed dose: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, immediate release:</b> Administer as soon as possible if ≥6 hours until next scheduled dose, otherwise, wait until next scheduled dose; do not double doses to compensate for missed dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, extended release [Canadian product]:</b> Administer as soon as possible if ≥8 hours until next scheduled dose, otherwise, wait until next scheduled dose; do not double doses to compensate for missed dose.</p>
<p style="text-indent:-2em;margin-left:2em;margin-right:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990660"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Ciprofloxacin Dosage Adjustments in Altered Kidney Function<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;">Oral, immediate release</p></th>
<th align="center">
<p style="text-indent:0em;">Oral, extended release <b>[Canadian product]</b></p></th>
<th align="center">
<p style="text-indent:0em;">IV</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Expert opinion derived from manufacturer's labeling, Heintz 2009, Mrhar 1990.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup>For severe infections, 750 mg may be administered at the intervals noted above.</p>
<p style="text-indent:0em;">
<sup>c</sup>Consider administering a loading dose of 400 mg × 1 if utilizing 200 mg every 24 hours.</p>
<p style="text-indent:0em;text-align:left;">
<sup>d</sup>Consider administering a loading dose of 500 mg × 1 if utilizing 250 mg every 24 hours.</p>
<p style="text-indent:0em;text-align:left;">
<sup>e</sup>Minimally dialyzable (&lt;10%); when scheduled dose falls on a dialysis day, administer post dialysis.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl &gt;50 to &lt;130</p></td>
<td align="center">
<p style="text-indent:0em;">500 to 750 mg every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg every 8 to 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl 30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;">250 to 500 mg every 12 hours<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg every 8 to 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl &lt;30</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">200<sup>c</sup> to 400 mg every 12 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hemodialysis, intermittent (thrice weekly)<sup>e</sup></p></td>
<td align="center">
<p style="text-indent:0em;">250<sup>d</sup> to 500 mg every 24 hours<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">200<sup>c</sup> to 400 mg every 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Peritoneal dialysis</p></td>
<td align="center">
<p style="text-indent:0em;">250<sup>d</sup> to 500 mg every 24 hours<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">200<sup>c</sup> to 400 mg every 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>): </b>Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post-trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 400 mg every 8 hours when organism minimum inhibitory concentration (MIC) ≤0.125 mg/L. Monte Carlo simulations suggest a dose of 600 mg every 8 hours may be required to achieve pharmacodynamic goals for organisms with MICs &gt;0.125 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30809648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30809648'])">Ref</a></span>); monitor closely, especially with prolonged courses, or utilize another agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 200 to 400 mg every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26957490','lexi-content-ref-21816053','lexi-content-ref-11398692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26957490','lexi-content-ref-21816053','lexi-content-ref-11398692'])">Ref</a></span>). <b>Note</b>: Utilize 400 mg every 8 hours only in severe infections or when difficult-to-treat organisms (MIC ≥0.5 mg/L) are suspected or confirmed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26957490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26957490'])">Ref</a></span>); monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, immediate release:</b> 250 to 750 mg every 12 hours (expert opinion inferred from relative IV clearance).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important. Dosing based on Monte Carlo simulations of 8- to 10-hour treatments with 4 to 5 L/hour flow rates.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 400 mg every 12 hours assuming MIC susceptibility breakpoint ≤0.5 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lewis.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lewis.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, immediate release:</b> 500 mg every 12 hours (administer after PIRRT) (expert opinion inferred from relative IV clearance).</p></div>
<div class="block doha drugH1Div" id="F50987878"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Initial or dose titration in patients with preexisting liver cirrhosis or dosage adjustment in patients with chronic, worsening hepatic function during treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A through C: IV, Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11990328','lexi-content-ref-2731404','lexi-content-ref-2836821','lexi-content-ref-2258353','lexi-content-ref-2292201','lexi-content-ref-35052907']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11990328','lexi-content-ref-2731404','lexi-content-ref-2836821','lexi-content-ref-2258353','lexi-content-ref-2292201','lexi-content-ref-35052907'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute worsening of hepatic function (eg, requiring hospitalization): </b>No dosage adjustment necessary; however, consider discontinuation of ciprofloxacin therapy in patients with suspected ciprofloxacin-induced liver injury unless the benefits outweigh the risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24879980','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24879980','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F9611425"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F9611423"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15951" href="/d/html/15951.html" rel="external">see "Ciprofloxacin (systemic): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosa</b>
<b>ge form information: </b>Oral liquid products are available in 2 concentrations (ie, 50 mg/mL and 100 mg/mL); verify product selection; use caution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Fluoroquinolones should not typically be used as first-line therapy due to their adverse effect profile and risk of development of bacterial resistance. Only use in situations when there is no safe and effective substitute available (eg, drug resistance, allergy) or when oral fluoroquinolone therapy provides a reasonable alternative to parenteral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800','lexi-content-ref-Nelsons.1','lexi-content-ref-26865283','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800','lexi-content-ref-Nelsons.1','lexi-content-ref-26865283','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release: 10 to 20 mg/kg/dose every 12 hours; maximum daily dose: 1,500 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 10 mg/kg/dose every 8 to 12 hours; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax:</b>
<b> Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis (inhalational exposure): </i>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release: 15 mg/kg/dose every 12 hours for 60 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 10 mg/kg/dose every 12 hours for 60 days; maximum dose: 400 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous, without systemic involvement; treatment:</i> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release: 15 mg/kg/dose every 12 hours; maximum dose: 500 mg/dose. For naturally acquired infection, treat for 7 to 10 days; for a biological weapon-related event, treat for up to 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe anthrax (eg, anthrax meningitis, inhalational anthrax, head or neck lesions, cutaneous anthrax with systemic involvement); treatment: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Administer as part of an appropriate combination regimen for ≥2 to 3 weeks and until patient is clinically stable. After completion of therapy, if exposure was due to spore inhalation, initiate antimicrobial prophylaxis to complete an antimicrobial course of 60 days from onset of illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial parenteral treatment: IV: 10 mg/kg/dose every 8 hours; maximum dose: 400 mg/dose; continue until clinical criteria for stability are met (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Oral step-down therapy: Oral: Immediate release: 15 mg/kg/dose every 12 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebb96f4a-2e09-4a6e-aa0c-a951ff7a4d9d">Campylobacteriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Campylobacteriosis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diarrhea:</i>
<b>Note:</b> Antibiotics are typically not required for uncomplicated enteritis in otherwise healthy patients; when antibiotics are indicated, other agents (eg, azithromycin) may be preferred due to widespread fluoroquinolone resistance in <i>Campylobacter</i> spp (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelsons.2','lexi-content-ref-30385582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelsons.2','lexi-content-ref-30385582'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months, Children, and Adolescents: Oral: Immediate release: 10 to 15 mg/kg/dose every 12 hours; maximum dose: 750 mg/dose. Usual duration: 3 to 5 days; patients with HIV may require 7 to 10 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelsons.2','lexi-content-ref-29290231','lexi-content-ref-HHS.4','lexi-content-ref-11099086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelsons.2','lexi-content-ref-29290231','lexi-content-ref-HHS.4','lexi-content-ref-11099086'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bacteremia in HIV-infected Adolescents:</i>
<b>Note: </b>Treat for ≥14 days for bacteremia, and 2 to 6 weeks for recurrent disease; consider use in combination with an aminoglycoside (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release: Adolescents: 500 to 750 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Adolescents: 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e2a56fe-ae38-44c3-9cbe-f0cf191e8b37">Chancroid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chancroid (<i>Haemophilus ducreyi</i>):</b> Limited data available: Children weighing ≥45 kg and Adolescents: Oral: Immediate release: 500 mg every 12 hours for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c9933de-5b35-45e3-9c98-4831d4c09f7f">Cholera infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholera (<i>Vibrio cholerae</i>) infection, treatment (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-dose regimen:</i> Infants, Children, and Adolescents: Oral: Immediate release: 20 mg/kg as a single dose; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.4','lexi-content-ref-GTFCC.1','lexi-content-ref-19578229','lexi-content-ref-AAP.1','lexi-content-ref-16182896','lexi-content-ref-29790845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.4','lexi-content-ref-GTFCC.1','lexi-content-ref-19578229','lexi-content-ref-AAP.1','lexi-content-ref-16182896','lexi-content-ref-29790845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Three-day regimen</i>: Infants, Children, and Adolescents: Oral: Immediate release: 15 mg/kg/dose twice daily for 3 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-29790845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-29790845'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d1d4c54-ef98-486f-9c71-c0e9856532b2">Cystic fibrosis, acute pulmonary exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, acute pulmonary exacerbation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: <b>Note: </b>Treatment duration varies and is dependent on patient-specific factors, including response to therapy; typical duration is 10 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31487382','lexi-content-ref-34588142','lexi-content-ref-27139161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31487382','lexi-content-ref-34588142','lexi-content-ref-27139161'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release: 20 mg/kg/dose every 12 hours; usual maximum dose: 750 mg/dose; higher maximum dose of 1,000 mg/dose has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22949224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22949224'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 10 mg/kg/dose every 8 hours; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22949224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22949224'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e455e7a-edf2-4fde-8585-04f16c471440">Endocarditis, culture negative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, culture negative:</b> Limited data available:<b> Note: </b>Administer as part of an appropriate combination regimen. In patients with native valve infection, treat for 4 to 6 weeks; in patients with late prosthetic valve infection, treat for 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release: 10 to 15 mg/kg/dose every 12 hours; maximum dose: 750 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 10 to 15 mg/kg/dose every 12 hours; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9938d465-584f-48f7-8083-e90bc984c47e">Exit-site or tunnel infection, peritoneal dialysis catheter</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exit-site or tunnel infection, peritoneal dialysis catheter:</b> Limited data available: Infants, Children, and Adolescents: Oral: Immediate release: 10 to 15 mg/kg/dose every 24 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection (alternative therapy):</b> Limited data available: <b>Note: </b>May be considered in lower-risk patients with community-acquired infection when beta-lactams cannot be tolerated; local susceptibility patterns should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 10 to 15 mg/kg/dose every 12 hours; maximum dose: 400 mg/dose. Treatment duration varies based on specific source of infection, success of source control procedures, and clinical response; a total duration of 5 days is typically recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="22b9b316-2e55-434d-884a-a716a70e536d">Meningitis or ventriculitis, health care-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis or ventriculitis, health care-associated (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 10 mg/kg/dose every 8 hours or 15 mg/kg/dose every 12 hours; maximum dose: 400 mg/dose. Duration of treatment varies based on isolated pathogen, cerebrospinal fluid studies, and clinical presentation; treat gram-negative pathogens for at least 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee503525-0e5d-4809-a500-384b58e44e0a">Meningococcal disease, chemoprophylaxis after close contact with a patient with invasive disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal disease (<i>Neisseria meningitidis)</i>, chemoprophylaxis after close contact with a patient with invasive disease:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: Immediate release: 20 mg/kg as a single dose; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54df90f8-80f1-472c-a2d6-9a605b827f80">Mycobacterium avium complex infection, disseminated disease; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Mycobacterium avium </i>complex infection, disseminated disease; treatment (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children with HIV: Oral: Immediate release: 10 to 15 mg/kg/dose every 12 hours as part of an appropriate combination regimen for ≥12 months; maximum dose: 750 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41129648-6270-4140-a988-6f61199b5333">Plague infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague (<i>Yersinia pestis)</i> infection: Note:</b> Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis</i>: Infants, Children, and Adolescents: Oral: Immediate release: 15 mg/kg/dose every 12 hours for 7 days; maximum dose: 750 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, excluding meningitis</i>: <b>Note: </b>Treat for a total of 10 to 14 days; therapy may be extended if clinical resolution not observed (eg, ongoing fever) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: Immediate release: 15 mg/kg/dose every 8 to 12 hours; maximum daily dose: 1,500 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 10 mg/kg/dose every 8 to 12 hours; maximum dose: 400 mg/dose; may transition to oral therapy if appropriate once clinically improved.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7641868-88a0-4c96-af33-f6e0e2c6bdd1">Pneumonia, community-acquired, due to <i>Haemophilus influenzae</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired, due to <i>Haemophilus influenzae</i> (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;3 months and Children: IV: 15 mg/kg/dose every 12 hours; maximum dose: 400 mg/dose. Transition to oral therapy when able for a total duration of 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587','lexi-content-ref-32525203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587','lexi-content-ref-32525203'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0cb5cc36-71b8-49ae-9f07-5c56d7869ba6">
<i>Salmonella</i> species infection, nontyphoidal; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Salmonella</i> species infection, nontyphoidal; treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents with HIV: <b>Note: </b>For gastroenteritis without bacteremia, treat for 7 to 14 days; if CD4 is &lt;200 cells/mm<sup>3</sup>, treat for 2 to 6 weeks, especially if illness was severe initially. For gastroenteritis with bacteremia, treat for ≥14 days, and longer if bacteremia persists or infection is complicated, or if CD4 is &lt;200 cells/mm<sup>3</sup> (up to 6 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release: 500 to 750 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a4ad2ab-7b91-4ae4-8b8e-bf5c4d2fcd46">Shigella diarrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Shigella diarrhea:</b> Limited data available: <b>Note:</b> Only use if MIC is &lt;0.12 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: Immediate release: 15 mg/kg/dose every 12 hours for 3 to 5 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelsons.2','lexi-content-ref-21829747','lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelsons.2','lexi-content-ref-21829747','lexi-content-ref-WHO.3'])">Ref</a></span>). Adolescents with HIV may require a longer duration (ie, 7 to 10 days) and higher doses up to 750 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Children and Adolescents: IV: 10 mg/kg as a single dose within 120 minutes prior to surgical incision; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf64d97c-215c-415e-9c7b-86a9dd06850a">Tularemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tularemia (<i>Francisella tularensis</i>) (alternative agent):</b> Limited data available: <b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment, mild disease:</i></p>
<p style="text-indent:-2em;margin-left:8em;">IV: 15 mg/kg/dose every 12 hours for 10 to 14 days; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.5','lexi-content-ref-11386933','lexi-content-ref-WHO.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.5','lexi-content-ref-11386933','lexi-content-ref-WHO.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: Immediate release: 15 mg/kg/dose every 12 hours for 10 to 14 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.5','lexi-content-ref-11386933','lexi-content-ref-WHO.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.5','lexi-content-ref-11386933','lexi-content-ref-WHO.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postexposure prophylaxis:</i> Oral: Immediate release: 15 mg/kg/dose twice daily for 14 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11386933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11386933'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Limited data available: Oral: Immediate release: 10 to 20 mg/kg/dose every 12 hours; maximum dose: 750 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25477258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25477258'])">Ref</a></span>). Treat for 3 to 5 days; children &lt;2 years of age may require a longer course (eg, 7 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693','lexi-content-ref-36009990','lexi-content-ref-29292282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693','lexi-content-ref-36009990','lexi-content-ref-29292282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Complicated (including pyelonephritis):</i>
<b>Note</b>: Treat for a total of 6 to 10 days; children &lt;2 years of age may require a longer course (eg, 7 to 14 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693','lexi-content-ref-36009990','lexi-content-ref-32364593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693','lexi-content-ref-36009990','lexi-content-ref-32364593'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release: Children and Adolescents: 10 to 20 mg/kg/dose every 12 hours; maximum dose: 750 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelsons.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelsons.2','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note: </b>When treating <i>Pseudomonas aeruginosa</i>, doses of 20 mg/kg/dose every 12 hours are recommended based on pharmacokinetic modeling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29987142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29987142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Children and Adolescents: 6 to 10 mg/kg/dose every 8 hours; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25477258','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25477258','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084794"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV, Oral (immediate release): There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 10 to 15 mg/kg/dose every 18 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 10 to 15 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodialysis/peritoneal dialysis (PD) (after dialysis on dialysis days): Minimally dialyzable (&lt;10%): 10 to 15 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">CRRT: 10 to 15 mg/kg/dose every 12 hours.</p></div>
<div class="block dohp drugH1Div" id="F51084795"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with caution in severe impairment.</p></div>
<div class="block arsc drugH1Div" id="F54460472"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Aortic aneurysm/aortic dissection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones have been associated with <b>aortic aneurysm</b> and <b>aortic dissection</b> with risk of aortic aneurysm higher than aortic dissection. Risk of aortic dissection may be lower with ciprofloxacin and moxifloxacin than with levofloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30809871','lexi-content-ref-31077091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30809871','lexi-content-ref-31077091'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; up-regulation of matrix metalloproteinase (MMP) enzymes capable of damaging components of the extracellular matrix, including collagen and elastin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15890441','lexi-content-ref-22035890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15890441','lexi-content-ref-22035890'])">Ref</a></span>). MMP-2 and MMP-9 have been shown to play a role in development of aneurysms via degradation of collagen fibril (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28739200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28739200'])">Ref</a></span>). May also have a direct effect on the viability of chondrocytes and tenocytes responsible for collagen synthesis, due to generation of reactive oxygen species, caspase activation, and apoptosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22615289','lexi-content-ref-15890441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22615289','lexi-content-ref-15890441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed in most cases. Studies evaluating risk generally evaluated the time period of 60 days after the initiation of fluoroquinolone therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31500468','lexi-content-ref-29519881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31500468','lexi-content-ref-29519881'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults with peripheral vascular disease or a history of aneurysms, atherosclerosis, hypertension, or genetic conditions predisposing to aortic aneurysm (eg, Marfan syndrome, Ehlers-Danlos syndrome) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30213330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30213330'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer courses of therapy (&gt;14 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30213330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30213330'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Severe emotional or physical stress has been correlated to the onset of pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17950810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17950810'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Arthropathy/arthralgia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Arthropathy, or joint disease, has been observed in both animal and pediatric human studies following treatment with fluoroquinolone antibiotics, including ciprofloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26865283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26865283'])">Ref</a></span>). In an international, multicenter, randomized trial of ~700 pediatric patients (ciprofloxacin versus comparator), more patients in the ciprofloxacin group experienced musculoskeletal events both within 6 weeks and 1 year of follow-up. Arthropathy and <b>arthralgias</b> appear to resolve after discontinuation of treatment with no long-term sequelae (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26865283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26865283'])">Ref</a></span>). Though the true incidence is unknown, arthropathy and arthralgia are considered to be infrequent, but potentially serious adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism<b>:</b></i> Unknown; several hypotheses have been proposed including inhibition of mitochondria DNA synthesis in immature chondrocytes, direct toxic effect of fluoride on cartilage, magnesium chelation and subsequent deficiency in cartilage, and defective proteoglycan and procollagen synthesis with decreased incorporation of tritiated thymidine by chondrocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26865283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26865283'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; may occur within first day of treatment initiation or months following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21785119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21785119'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800','lexi-content-ref-26865283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800','lexi-content-ref-26865283'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects/neuroexcitation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones have been associated with a range of psychiatric and neurologic effects, ranging from <b>dizziness</b> and <b>restlessness</b> to <b>toxic psychosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29702230','lexi-content-ref-21585220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29702230','lexi-content-ref-21585220'])">Ref</a></span>). More common reactions include <b>confusion</b>, <b>agitation</b>, <b>insomnia</b>, and <b>drowsiness</b>. More severe reactions, including delusions, <b>hallucinations</b>, <b>suicidal ideation</b>, <b>suicidal tendencies</b>, and toxic psychosis, are less common. Neuroexcitation may include <b>seizure</b> in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20397737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20397737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> GABA binding disruption, NMDA binding alterations, and increased excitatory neurotransmitters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8390432','lexi-content-ref-20397737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8390432','lexi-content-ref-20397737'])">Ref</a></span>). Mitochondrial dysfunction has been hypothesized to contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28063266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28063266'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; neuroexcitatory phenomena generally occur in the first week of therapy, often after 2 to 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21585220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21585220'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25450476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25450476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment with unadjusted or higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26400582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26400582'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with enhanced neuroexcitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25450476','lexi-content-ref-21585220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25450476','lexi-content-ref-21585220'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent theophylline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25450476','lexi-content-ref-26400582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25450476','lexi-content-ref-26400582'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of seizures, seizure disorders, CNS disorders, or concurrent therapy with medications known to lower seizure threshold may increase risk of seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26400582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26400582'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of or risk factor for mental illness (eg, depression)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection (CDI), including <i>Clostridioides difficile</i> associated diarrhea and <i>Clostridioides difficile</i> colitis, has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1976960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1976960'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (fluoroquinolones among the highest risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospital or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors and H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Glucose regulation/dysglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperglycemia</b> and <b>hypoglycemia</b> have been associated with the use of fluoroquinolones, including ciprofloxacin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Increase in insulin release via blockade of adenosine triphosphate-sensitive potassium channels in the pancreatic beta cells, but the significance at clinical concentrations has been questioned (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19073153','lexi-content-ref-24284031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19073153','lexi-content-ref-24284031'])">Ref</a></span>). Additionally, effects on gluconeogenesis, glucose transport (via expression of GLUT-1), and mitochondrial dysfunction have been implicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19022360','lexi-content-ref-32004540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19022360','lexi-content-ref-32004540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; corresponds to the initiation of therapy but may be delayed by 2 to 3 days. Events requiring emergent care or hospitalization occurred between day 3 and day 10 of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23948133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23948133'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with diabetes are at highest risk; however, cases in patients without diabetes have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31078137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31078137'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapy with hypoglycemic agents, including insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23948133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23948133'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin may cause hepatic injury (<b>hepatotoxicity</b>); both cholestatic and hepatocellular patterns are represented in reported clinical presentations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24352180','lexi-content-ref-21356330','lexi-content-ref-30266895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24352180','lexi-content-ref-21356330','lexi-content-ref-30266895'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Immunologic reactions account for many events; direct toxicity related to mitochondrial dysfunction and increased oxidative stress may also be responsible for some reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21356330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21356330'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; acute liver injury may occur in a range of 1 to 39 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Most fatal events occurred in patients &gt;55 years of age</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reactions</b> include <b>anaphylaxis</b>, <b>nonimmune anaphylaxis</b>, and delayed cutaneous reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">Delayed cutaneous reactions include severe dermatologic reactions, <b>acute generalized exanthematous pustulosis</b>, <b>drug reaction with eosinophilia and systems symptoms</b>, <b>Stevens-Johnson syndrome</b>, and <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24340128','lexi-content-ref-28458435','lexi-content-ref-14576649','lexi-content-ref-16205075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24340128','lexi-content-ref-28458435','lexi-content-ref-14576649','lexi-content-ref-16205075'])">Ref</a></span>). Less severe reactions include nonbullous and bullous<b> fixed drug eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29866687','lexi-content-ref-31135195','lexi-content-ref-25949980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29866687','lexi-content-ref-31135195','lexi-content-ref-25949980'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Immunologically mediated organ-specific reactions include <b>pneumonitis</b>, <b>vasculitis</b>, <b>pancreatitis</b>, <b>interstitial nephritis</b>, <b>hemolytic anemia</b>,<b> thrombocytopenia</b>, and some cases of hepatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12022900','lexi-content-ref-29157532','lexi-content-ref-28070469','lexi-content-ref-30266895','lexi-content-ref-28791716','lexi-content-ref-14738249','lexi-content-ref-24827622']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12022900','lexi-content-ref-29157532','lexi-content-ref-28070469','lexi-content-ref-30266895','lexi-content-ref-28791716','lexi-content-ref-14738249','lexi-content-ref-24827622'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Nonimmune anaphylaxis results from binding directly to specific receptors (MGPRX2) on mast cells and basophils, causing direct stimulation of histamine release (and other mediators) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30856392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30856392'])">Ref</a></span>). Importantly, these cases may occur without prior exposure. In other cases, anaphylaxis may be mediated by IgE, formed with prior exposure to the drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14713922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14713922'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed reactions are mediated by activated T-cells. Chemical activation of fluoroquinolones was not required for immune reactions to occur, which implies direct activation (pharmacologic interaction) without covalent binding to host proteins/hapten formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16393267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16393267'])">Ref</a></span>). Ciprofloxacin forms metabolites, but haptens have not been characterized to date.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Anaphylaxis (nonimmune and immune): Rapid; may occur within an hour of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30401472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30401472'])">Ref</a></span>). Other reactions, particularly various maculopapular cutaneous reactions or organ-specific reactions: Varied; occur after days to weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24340128','lexi-content-ref-14576649','lexi-content-ref-20399988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24340128','lexi-content-ref-14576649','lexi-content-ref-20399988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Nonimmune anaphylaxis may be dose- and/or infusion rate-related (concentration-related) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30856392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30856392'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myasthenia gravis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones, including ciprofloxacin, may cause an <b>exacerbation of</b>
<b>myasthenia gravis</b>. Disease exacerbations vary in severity from muscular weakness to severe compromise (myasthenic crisis characterized by acute respiratory failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21879778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21879778'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Neuromuscular blockade is the most frequently cited mechanism, although alterations in mitochondrial energy production has also been suggested as a contributing mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21879778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21879778'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; within hours of the initiation of therapy with a fluoroquinolone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21879778','lexi-content-ref-2224281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21879778','lexi-content-ref-2224281'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Patients with myasthenia gravis (diagnosed and undiagnosed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2224281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2224281'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral neuropathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones have been associated with <b>peripheral neuropathy</b> and other effects, including axonal neuropathy and <b>Guillain-Barré syndrome</b> (GBS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24472364','lexi-content-ref-29928218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24472364','lexi-content-ref-29928218'])">Ref</a></span>). Associated with many types of disturbances of special senses, including several case reports indicating a very slow recovery and/or permanent state of disability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11793615','lexi-content-ref-26425618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11793615','lexi-content-ref-26425618'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Mitochondrial effects related to reactive oxygen species and apoptotic changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19022360','lexi-content-ref-32004540','lexi-content-ref-25902267','lexi-content-ref-23825301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19022360','lexi-content-ref-32004540','lexi-content-ref-25902267','lexi-content-ref-23825301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may present as early as the first day of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11793615','lexi-content-ref-26425618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11793615','lexi-content-ref-26425618'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31034074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31034074'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older adults (&gt;60 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31034074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31034074'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31034074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31034074'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Type 1 diabetes may also be a risk factor (data are limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29511692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29511692'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> History of peripheral neuropathy</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Phototoxicity/photoallergy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Phototoxicity/skin photosensitivity</b> account for a proportion of the overall cutaneous adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30003982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30003982'])">Ref</a></span>). Published reports with ciprofloxacin are limited; may be more common with other fluoroquinolones (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8320021','lexi-content-ref-22971191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8320021','lexi-content-ref-22971191'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; immunologic. Reactive intermediates are generated by ultraviolet exposure and attach to proteins of Langerhans cells, triggering immune reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10692119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10692119'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in a study with ofloxacin, occurred within 24 hours of initiation and sun exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8320021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8320021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Duration and intensity of sun exposure</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Cystic fibrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22971191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22971191'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Prior phototoxic reaction to another fluoroquinolone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9536423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9536423'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones may be associated with <b>prolonged QT interval on ECG</b> and ventricular arrhythmias, such as <b>torsades de pointes</b> (TdP). Ciprofloxacin may have a lower risk than other fluoroquinolones, particularly moxifloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30368737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30368737'])">Ref</a></span>). Change in QTc from baseline for moxifloxacin was found to be +16.34 to 17.83 ms, while the change with ciprofloxacin was +2.27 to 4.93 ms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12709719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12709719'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May alter the rapid delayed rectifier potassium current, resulting in prolonged repolarization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24428853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24428853'])">Ref</a></span>). Prolonged repolarization can alter action potentials in cardiac cells and promote arrhythmogenic activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31029713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31029713'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; effect is concentration-dependent, initially observed at supra-therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11125032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11125032'])">Ref</a></span>). High dose or accumulation may influence concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QT interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Loop diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent administration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QT prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tendinopathy/tendon rupture</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin may cause <b>tendinopathy</b> or <b>rupture of tendon</b>; Achilles is most commonly cited, but inflammation/rupture of many other tendons (including hand, rotator cuff, biceps, and thumb) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26393387']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26393387'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; upregulation of matrix metalloproteinase (MMP) enzymes capable of damaging components of the extracellular matrix, including collagen and elastin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15890441','lexi-content-ref-22035890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15890441','lexi-content-ref-22035890'])">Ref</a></span>). Direct effect on the viability of chondrocytes and tenocytes responsible for collagen synthesis, due to generation of reactive oxygen species, caspase activation and apoptosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22615289','lexi-content-ref-30811525','lexi-content-ref-20034766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22615289','lexi-content-ref-30811525','lexi-content-ref-20034766'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; per the manufacturer's labeling, tendinopathy or tendon rupture may occur within hours or days of initiation or may be delayed for several months after discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564','lexi-content-ref-20034766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564','lexi-content-ref-20034766'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous tendon disorders (eg, rheumatoid arthritis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Solid organ transplant recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Strenuous physical activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy and higher dosages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F9611304"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Neuromuscular &amp; skeletal: Musculoskeletal signs and symptoms (children: 9% to 22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children: 3%; adults: &lt;1%), diarrhea (2% to 5%), dyspepsia (1% to 3%), nausea (3% to 4%), vomiting (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vulvovaginal candidiasis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reactions (IV: &gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (oral: 2%; IV: &lt;1%), drowsiness, headache (oral: 1% to 3%; IV: &gt;1%), insomnia, nervousness, neurological signs and symptoms (IV: children: 3%), restlessness (IV: &gt;1%; oral: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (children: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children: 2%; adults: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, flushing, hypertension, hypotension, syncope, tachycardia, thrombophlebitis, vasculitis, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, erythema multiforme, erythema nodosum, exfoliative dermatitis, phototoxicity, pruritus, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, gynecomastia, hyperglycemia, hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, anorexia, <i>Clostridioides difficile</i> colitis, constipation, dysgeusia, flatulence, gastrointestinal hemorrhage, intestinal obstruction, intestinal perforation, oral mucosa ulcer, pancreatitis, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Crystalluria, hematuria, hemorrhagic cystitis, urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, petechia, prolonged prothrombin time, purpuric disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatic necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, anosmia, asthenia, ataxia, burning sensation, confusion, depersonalization, depression, hallucination, hypertonia, irritability, malaise, manic reaction, migraine, myasthenia, nightmares, pain, paranoid ideation, paresthesia, phobia, seizure, status epilepticus, suicidal ideation, suicidal tendencies, taste disorder, toxic psychosis, tremor, unresponsive to stimuli</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, joint stiffness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, chromatopsia, decreased visual acuity, diplopia, nystagmus disorder, photopsia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, casts in urine, interstitial nephritis, nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea, hemoptysis, laryngeal edema</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Aortic aneurysm (Meng 2018; Pasternak 2018), aortic dissection (Meng 2018; Pasternak 2018), bradycardia (Cordova Sanchez 2022), prolonged QT interval on ECG (Teng 2019), torsades de pointes (Teng 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Foti 2017; Hauserman 2005), fixed drug eruption (Illiyas 2019; Mollica 2019; Nair 2015), maculopapular rash (Kulthanan 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, <i>Clostridioides difficile</i> associated diarrhea (Bates 1990; Hillman 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (Dutta 1999), eosinophilia (Dutta 1999; Hootkins 1989), hemolytic anemia (Lim 2003), leukopenia (Dutta 1999), lymphocytosis (Dutta 1999), methemoglobinemia, monocytosis (Dutta 1999), pancytopenia (Dutta 1999), thrombocythemia, thrombocytopenia (Dutta 1999; Sim 2018), thrombocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Cholongitas 2009), hepatic failure, hepatotoxicity (Alshammari 2014; Orman 2011; Radovanovic 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Alkhateeb 2013), nonimmune anaphylaxis (Ouni 2019), serum sickness-like reaction (Slama 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety, delirium (Yousafzai 2022), disturbance in attention, exacerbation of myasthenia gravis (Jones 2011), Guillain-Barré syndrome (Ali 2014), hyperesthesia, hypoesthesia, increased intracranial pressure, intracranial hypertension (Tan 2019), memory impairment, myoclonus (van Samkar 2017), peripheral neuropathy (may be irreversible) (Ali 2014; Francis 2014; Popescu 2018), polyneuropathy, reversible posterior leukoencephalopathy syndrome (Ali 2013), twitching</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Exacerbation of systemic lupus erythematous (Liaqat 2020), myalgia, rupture of tendon (Arabyat 2015; van der Linden 2002; Yu 2019), tendinopathy (van der Linden 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinal detachment (inconsistent data) (Shin 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis (including interstitial pneumonitis) (Steiger 2004)</p></div>
<div class="block coi drugH1Div" id="F9611301"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ciprofloxacin, any component of the formulation, or other quinolones; concurrent administration of tizanidine</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Concurrent administration of agomelatine</p></div>
<div class="block war drugH1Div" id="F9611302"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Crystalluria: Rarely, crystalluria has occurred; urine alkalinity may increase the risk. Ensure adequate hydration during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Syphilis: Since ciprofloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Adverse effects (eg, tendon rupture, QT changes) may be increased in elderly patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Hemolytic reactions may (rarely) occur with fluoroquinolone use in patients with G6PD deficiency (Luzzatto 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Adverse effects, including those related to joints and/or surrounding tissues, are increased in pediatric patients and therefore, ciprofloxacin should not be considered as drug of choice in children (exception is anthrax treatment).</p></div>
<div class="block dosfc drugH1Div" id="F58341678"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">ER tablets [Canadian product] and IR formulations are not interchangeable.</p></div>
<div class="block foc drugH1Div" id="F9611523"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/100 mL (100 mL); 400 mg/200 mL (200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/100 mL (100 mL); 400 mg/200 mL (200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cipro: 250 mg/5 mL (100 mL); 500 mg/5 mL (100 mL) [strawberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/5 mL (100 mL [DSC]); 500 mg/5 mL (100 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cipro: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg [DSC], 250 mg, 500 mg, 750 mg</p></div>
<div class="block geq drugH1Div" id="F9611236"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9611525"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ciprofloxacin in D5W Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/100 mL (per mL): $0.02 - $0.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg/200 mL (per mL): $0.01 - $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Cipro Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 MG/5ML (5%) (per mL): $1.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 MG/5ML (10%) (per mL): $1.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cipro Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $5.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $6.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ciprofloxacin HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $2.24 - $4.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.35 - $5.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $5.45 - $6.19</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868810"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL in D5W (100 mL, 200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cipro: 500 mg/5 mL (100 mL) [contains soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cipro: 500 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 250 mg, 500 mg, 750 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as base and hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cipro XL: 500 mg [DSC], 1000 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block adm drugH1Div" id="F9611451"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May administer with most foods to minimize GI upset; avoid antacid use; maintain proper hydration and urine output. Avoid concomitant administration with dairy products (eg, milk, yogurt) or calcium-fortified products alone; however, may be taken with meals that contain these products; separate administration of extended-release tablets [Canadian product] and calcium &gt;800 mg by at least 2 hours. Administer all oral ciprofloxacin formulations at least 2 hours before or 6 hours after antacids or other products containing calcium, iron, or zinc. Separate oral administration from drugs that may impair absorption (see "Drug Interactions").</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral suspension:</b> Should not be administered through feeding tubes (suspension is oil-based and adheres to the feeding tube). Shake vigorously before use for ~15 seconds; administer using the co-packaged graduated teaspoon. Do not chew the microcapsules in the suspension; swallow whole.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nasogastric/orogastric tube:</b> Crush immediate-release tablet and mix with 20 to 60 mL water. Flush feeding tube before and after administration. Do not administer simultaneously with enteral nutrition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Beckwith.1','lexi-content-ref-8787869']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Beckwith.1','lexi-content-ref-8787869'])">Ref</a></span>). Optimal time frame for dose separation is unknown; one recommendation is to hold tube feedings at least 2 hours before and 4 hours after administration, which may require adjustment of feeding rates to compensate for lost feeding time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Beckwith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Beckwith.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet, extended release</b> [Canadian product]: Do not crush, split, or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation (tablet or oral solution).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral:</b> Administer by slow IV infusion over 60 minutes into a large vein (reduces risk of venous irritation).</p></div>
<div class="block admp drugH1Div" id="F52614214"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with food to minimize GI upset; avoid concomitant administration with dairy products (eg, milk, yogurt) or calcium-fortified juices alone; however, may be taken with meals that contain these products. Administer ≥2 hours before or 6 hours after antacids or other products containing calcium, iron, or zinc; see drug interactions database for details. Maintain adequate hydration and urine output.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Shake vigorously for ~15 seconds prior to each dose. Should not be administered through feeding tubes (suspension is oil-based and adheres to the feeding tube). Do not chew the microcapsules in the suspension; swallow whole.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose:</i> Immediate release (oral suspension, tablet): Administer as soon as possible if ≥6 hours until next scheduled dose; otherwise, wait until next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasogastric/orogastric tube: Do not administer commercially available oral suspension via feeding tube; however, an extemporaneously compounded solution may be prepared with immediate-release tablets or tablets may be crushed and administered.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release tablet: Crush immediate-release tablet and mix with at least 20 mL water, rinsing container to ensure all drug is administered. Flush feeding tube before and after administration. Do not administer simultaneously with enteral nutrition; optimal time frame for dose separation is unknown. One recommendation is to hold tube feedings for 2 hours before and 4 hours after dose administration, which may require adjustment of feeding rates to compensate for lost feeding time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Beckwith.1','lexi-content-ref-8787869','lexi-content-ref-9840238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Beckwith.1','lexi-content-ref-8787869','lexi-content-ref-9840238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer by slow IV infusion over 60 minutes to reduce the risk of venous irritation (burning, pain, erythema, and swelling).</p></div>
<div class="block meg drugH1Div" id="F9611231"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Cipro: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F019857s073lbl.pdf%23page%3D33&amp;token=NyKR1Gr7%2FRUVuorKQNxRo%2Fs9blKdfe305aktcQxXhXYdF608pofddFbTWmFLYWYyMz61BMxrSiVZ9i1tVBeRqM77c5%2Boi9cTvcgxsCS1%2FzhI8TYuN2wEDPUqXyVINzc6&amp;TOPIC_ID=9053" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019857s073lbl.pdf#page=33</a></p></div>
<div class="block use drugH1Div" id="F9611256"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents: Treatment of complicated urinary tract infections and pyelonephritis due to <i>E. coli</i>. <b>Note:</b> Although effective, ciprofloxacin is not the drug of first choice in children.</p>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, Adolescents, and Adults: Prophylaxis to reduce incidence or progression of disease following inhalation exposure to <i>Bacillus anthracis</i>; prophylaxis and treatment of plague (<i>Yersinia pestis</i>).</p>
<p style="text-indent:-2em;margin-left:2em;">Adults: Treatment of the following infections when caused by susceptible bacteria: Urinary tract infection; acute uncomplicated cystitis in females, chronic bacterial prostatitis, acute bacterial exacerbations of chronic bronchitis, acute bacterial rhinosinusitis, skin and soft tissue infections, bone and joint infections, complicated intra-abdominal infections (in combination with metronidazole), infectious diarrhea, typhoid fever (<i>Salmonella typhi),</i> hospital-acquired (nosocomial) pneumonia.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Because fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinopathy and tendon rupture, peripheral neuropathy, CNS effects), reserve ciprofloxacin for use in patients who have no alternative treatment options for acute uncomplicated cystitis, acute bacterial rhinosinusitis, and for acute exacerbations of chronic bronchitis when treatment is necessary.</p></div>
<div class="block off-label drugH1Div" id="F25475322"><span class="drugH1">Use: Off-Label: Adult</span><p>Anthrax; Bite wound infection (animal and human bites); Cat scratch disease, lymphadenitis (nondisseminated); Chancroid; Cholera (Vibrio cholerae); Chronic obstructive pulmonary disease, acute exacerbation; Crohn disease, treatment of simple perianal fistulas; Diabetic foot infection; Endocarditis, treatment; Meningitis, bacterial; Meningococcal disease (prevention and control); Neutropenia (chemotherapy-induced), antibacterial prophylaxis; Neutropenic fever, low-risk cancer patients (empiric therapy); Peritoneal dialysis catheter-related infection; Pouchitis (post–ileal pouch-anal anastomosis), acute; Prostatitis, acute bacterial; Prosthetic joint infection; Spontaneous bacterial peritonitis, prophylaxis; Surgical prophylaxis; Tularemia</p></div>
<div class="block mst drugH1Div" id="F3198418"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ciprofloxacin may be confused with cephalexin </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cipro may be confused with Ceftin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9611328"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3, P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (moderate), CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F9611329"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Quinolones may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agomelatine: Ciprofloxacin (Systemic) may increase the serum concentration of Agomelatine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron.  Management: Avoid concomitant use of alosetron and moderate CYP1A2 inhibitors whenever possible. If combined use is necessary, monitor for increased alosetron effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the cardiotoxic effect of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: CYP1A2 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Anagrelide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone; see full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Ciprofloxacin (Systemic) may increase the serum concentration of Asenapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ataluren: May increase the serum concentration of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bendamustine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bendamustine.  Management: Consider alternatives to moderate CYP1A2 inhibitors during therapy with bendamustine due to the potential for increased bendamustine plasma concentrations and increased bendamustine toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromazepam: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bromazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Caffeine and Caffeine Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents. Management: Consider administering an oral quinolone at least 2 hours before or 6 hours after the dose of oral calcium to minimize this interaction. Monitor for decreased therapeutic effects of quinolones during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: May enhance the hyperglycemic effect of Ciprofloxacin (Systemic). Chloroquine may enhance the hypoglycemic effect of Ciprofloxacin (Systemic). Chloroquine may enhance the QTc-prolonging effect of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Ciprofloxacin (Systemic) may enhance the QTc-prolonging effect of CloZAPine. Ciprofloxacin (Systemic) may increase the serum concentration of CloZAPine.  Management: Reduce the clozapine dose to one-third of the original dose when adding ciprofloxacin and monitor closely for evidence of excessive QTc prolongation and clozapine toxicity.  Resume the previous clozapine dose following ciprofloxacin discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Ciprofloxacin (Systemic) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid.  Management: Avoid concomitant use if possible. If coadministration is unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Ciprofloxacin (Systemic) may increase the serum concentration of Erlotinib.  Management: Avoid use of this combination when possible.  When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Management: Avoid use of fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May enhance the QTc-prolonging effect of Ciprofloxacin (Systemic). Ciprofloxacin (Systemic) may diminish the therapeutic effect of Fosphenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: May enhance the hyperglycemic effect of Ciprofloxacin (Systemic). Hydroxychloroquine may enhance the hypoglycemic effect of Ciprofloxacin (Systemic). Hydroxychloroquine may enhance the QTc-prolonging effect of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, oflox-, peflox, or nalidixic acid) oral iron.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: Ciprofloxacin (Systemic) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Ciprofloxacin (Systemic) may increase the serum concentration of Lumateperone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar/enox-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe/enox-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meptazinol: May decrease the serum concentration of Ciprofloxacin (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Ciprofloxacin (Systemic) may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May enhance the cardiotoxic effect of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Administer oral quinolones at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (ie, calcium, iron, magnesium, selenium, zinc). Monitor for decreased quinolone efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Administer oral quinolones at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (ie, calcium, iron, magnesium, selenium, zinc). Monitor for decreased therapeutic effects of quinolones.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Patiromer: May decrease the serum concentration of Ciprofloxacin (Systemic). Management: Administer oral ciprofloxacin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: Ciprofloxacin (Systemic) may diminish the therapeutic effect of Phenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirfenidone: Ciprofloxacin (Systemic) may increase the serum concentration of Pirfenidone.  Management: Avoid this combination if possible. With ciprofloxacin doses of 1,500 mg/day, the pirfenidone dose should be reduced to 1,602 mg per (534 mg three times a day). With lower daily doses of ciprofloxacin, use pirfenidone with caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Quinolones. Management: Give oral quinolones at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: Ciprofloxacin (Systemic) may increase the serum concentration of Pomalidomide.  Management: Avoid concomitant use of pomalidomide and ciprofloxacin when possible. If coadministration is considered necessary, consider reducing the pomalidomide dose to 2 mg and monitoring patients for increased pomalidomide effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline.  Management: Limit rasagiline dose to 0.5 mg once daily in patients taking moderate CYP1A2 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: Ciprofloxacin (Systemic) may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPivacaine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sevelamer: May decrease the serum concentration of Ciprofloxacin (Systemic). Management: Administer ciprofloxacin at least 2 hours before or 6 hours after sevelamer administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: Ciprofloxacin (Systemic) may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: Ciprofloxacin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Ciprofloxacin (Systemic) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May enhance the arrhythmogenic effect of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the serum concentration of Quinolones. Management: Avoid concurrent administration of quinolones and sucralfate to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Theophylline Derivatives.  Management: Consider avoidance of this combination. If coadministration is necessary, monitor for increased theophylline serum concentrations and toxicities when combined. Theophylline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Ciprofloxacin (Systemic) may decrease the serum concentration of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: Ciprofloxacin (Systemic) may increase the serum concentration of TiZANidine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: Ciprofloxacin (Systemic) may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and consider avoiding a second dose for 24 hours when used with ciprofloxacin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: Ciprofloxacin (Systemic) may increase the serum concentration of Zolpidem.  Management: Consider avoiding the combination of ciprofloxacin and zolpidem if possible. If combined, monitor for signs of zolpidem toxicity (eg, somnolence, dizziness, lethargy).<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F9611333"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases rate, but not extent, of absorption. Ciprofloxacin may increase serum caffeine levels if taken concurrently. Rarely, crystalluria may occur. Enteral feedings may decrease plasma concentrations of ciprofloxacin probably by &gt;30% inhibition of absorption. Management: May administer with most foods to minimize GI upset. If unable to avoid concomitant administration with dairy products or calcium-fortified products alone, administer ciprofloxacin at least 2 hours before or 6 hours after these foods/products; however, may be taken with meals that contain these products. Separate administration of extended-release tablets [Canadian product] and calcium &gt;800 mg by at least 2 hours. Restrict caffeine intake if excessive cardiac or CNS stimulation occurs. Ensure adequate hydration during therapy. Ciprofloxacin should not be administered with enteral feedings. The feeding would need to be discontinued for 1 to 2 hours prior to and after ciprofloxacin administration. Nasogastric administration produces a greater loss of ciprofloxacin bioavailability than does nasoduodenal administration.</p></div>
<div class="block pri drugH1Div" id="F9611260"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ciprofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid and cord serum (Ludlam 1997).</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, an increased risk of major birth defects, miscarriage, or other adverse fetal and maternal outcomes have not been observed following ciprofloxacin use during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of ciprofloxacin may be altered. Serum concentrations of ciprofloxacin may be lower during pregnancy than in nonpregnant patients (Giamarellou 1989).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated plague (<i>Yersinia pestis</i>) infections in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of <i>Y. pestis</i> can occur if not treated. Pregnant patients should be treated for <i>Y. pestis; </i>parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Ciprofloxacin is one of the fluroquinolones recommended for use (in combination with an aminoglycoside) for treating pregnant patients with bubonic, pharyngeal, pneumonic, or septicemic plague. Ciprofloxacin may also be used for pre- and postexposure prophylaxis in pregnant patients exposed to <i>Y. pestis.</i> Dose adjustments may be required (CDC [Nelson 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Ciprofloxacin is recommended for prophylaxis and treatment of pregnant patients exposed to anthrax (Meaney-Delman 2014). Alternative antibiotics are recommended in pregnant patients for indications such as chancroid (CDC [Workowski 2021]), meningococcal disease (CDC [Cohn 2013]), or perianal disease and pouchitis in pregnant patients with inflammatory bowel disease (AGA [Mahadevan 2019]).</p></div>
<div class="block brc drugH1Div" id="F9611300"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to the presence of ciprofloxacin in breast milk is available from 10 lactating women given oral ciprofloxacin 750 mg every 12 hours for 3 doses. Average milk concentrations were highest 2 hours after the dose (3.79 mcg/mL) and decreased to 0.02 mcg/mL 24 hours after the last dose (Giamarellou 1989). Using the milk concentration of 3.79 mcg/mL, another author has estimated the potential infant dosage via breastfeeding would be ≤0.569 mg/kg/day (Chung 2002), providing a relative infant dose (RID) of 2.8%, based on an infant therapeutic dose of 20 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">There is a case report of perforated pseudomembranous colitis in a breastfeeding infant whose mother was taking ciprofloxacin (Harmon 1992). In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">The risk for transmission of plague (<i>Y. pestis</i>) via breast milk is considered low. Patients with pneumonic plague can breastfeed if both the mother and infant are receiving antibiotic treatment or the infant is receiving postexposure prophylaxis, considering the risk of exposure to the drug via breast milk. If the infant is not being treated, breast milk should be expressed for at least 48 hours of maternal antibiotic therapy to limit person-to-person contact with the infant. The expressed breast milk may be given to the infant. Once maternal clinical improvement is observed, direct breastfeeding may resume. Patients taking ciprofloxacin for the treatment of plague can decrease infant exposure via breast milk by feeding 3 to 4 hours after the dose (CDC [Nelson 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin is recommended for the prophylaxis and treatment of <i>Bacillus anthracis</i> in breastfeeding patients (Meaney-Delman 2014). Alternative antibiotics are recommended in breastfeeding patients for the treatment of chancroid (CDC [Workowski 2021]) or meningococcal disease (CDC [Cohn 2013]). In general, quinolone antibiotics should be avoided in breastfeeding patients if alternative agents are available (WHO 2002). Based on adverse outcomes observed in animal studies, the manufacturer recommends that breastfeeding be discontinued during therapy and for 2 days after the last ciprofloxacin dose if used for indications other than treating maternal <i>B. anthracis</i>. Mothers may express and discard milk during this time.</p></div>
<div class="block dic drugH1Div" id="F9611450"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Food: May be taken with meals that contain dairy products (eg, milk, yogurt) or calcium-fortified products, but not with these products alone; separate administration of extended-release tablets [Canadian product] and calcium &gt;800 mg by at least 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine: Patients consuming regular large quantities of caffeinated beverages may need to restrict caffeine intake if excessive cardiac or CNS stimulation occurs.</p></div>
<div class="block mop drugH1Div" id="F9611455"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, renal and hepatic function during prolonged therapy, altered mental status, signs and symptoms of tendinopathy (tendon pain, swelling, inflammation, or rupture) or peripheral neuropathy; signs and symptoms of disordered glucose regulation (especially in patients with diabetes mellitus); rash; signs and symptoms of hypersensitivity reaction.</p></div>
<div class="block pha drugH1Div" id="F9611370"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA</p></div>
<div class="block phk drugH1Div" id="F9611373"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well-absorbed; 500 mg orally every 12 hours produces an equivalent AUC to that produced by 400 mg IV over 60 minutes every 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Tissue concentrations often exceed serum concentrations, especially in kidneys, gallbladder, liver, lungs, gynecological tissue, and prostatic tissue.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (GA: 23 to 42 weeks; PNA: 5 to 121 days): Median: 2.02 L/kg; range: 0.4 to 3.55 L/kg (Zhao 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 2 to 3 L/kg (Canadian manufacturer's labeling); reported range: 1.74 to 5 L/kg (Vance-Bryan 1990).</p>
<p style="text-indent:-2em;margin-left:4em;">Cerebrospinal fluid concentrations: Adolescents ≥16 years and Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">Noninflamed meninges: 2.9% to 40% (4 to 10 hours after dose) (Gogos 1991).</p>
<p style="text-indent:-2em;margin-left:6em;">Inflamed meninges: 24.1% to 91.1% (1 to 9 hours after dose) (Gogos 1991).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 20% to 40%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Partially hepatic; forms 4 metabolites (limited activity).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Children: ~60% (oral suspension); Adults: 70%; younger cystic fibrosis patients have a lower bioavailability of 68% versus cystic fibrosis patients &gt;13 years of age with bioavailability of 95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months, Children, and Adolescents: 4.2 to 5.1 hours (Peltola 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Children ≥5 years and Adolescents with cystic fibrosis:</i> Mean range: 2.6 to 3.4 hours (Rubio 1997).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Normal renal function: 4 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet: 0.5 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (35% to 70% as unchanged drug); feces (15% to 35%; &lt;1% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (GA: 23 to 42 weeks; PNA: 5 to 121 days): Median: 0.2 L/hour/kg; range: 0.04 to 0.81 L/hour/kg (Zhao 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: 0.48 L/hour/kg (Hirt 2021).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Children ≥5 years and Adolescents with cystic fibrosis:</i> Mean range: 0.84 to 1.16 L/hour/kg (Rubio 1997).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.5 to 0.6 L/hour/kg.</p></div>
<div class="block phksp drugH1Div" id="F51220840"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The half-life is prolonged.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: C<sub>max</sub> increased 16% to 40%, AUC increased approximately 20% to 30%, and half-life increased approximately 20%.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Concentration dependent, associated with AUC<sub>24</sub>/minimum inhibitory concentration (MIC), goal: ≥125 (&gt;80% clinical and microbiologic cures) (Forrest 1993); and C<sub>max</sub>(peak)/MIC ≥10 (bactericidal, resistance prevention) (Blaser 1987; Drusano 1993). <b>Note: </b>In critically ill patients, some experts recommend AUC<sub>24</sub>/MIC goal &gt;125 to 250 and C<sub>max</sub>/MIC ≥12 (Abdul-Aziz 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Expected drug exposure in patients with normal renal function:</p>
<p style="text-indent:-2em;margin-left:6em;">AUC<sub>24</sub>:</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients: 10 mg/kg/dose 3 times daily (multiple dose): IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Neonates and infants: 30.9 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children &lt;2 years of age: 27.8 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 2 to &lt;6 years of age: 28.9 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 6 to &lt;12 years of age: 20.4 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:8em;">Adults (multiple dose):</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg twice daily: Oral: 27.4 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">750 mg twice daily: Oral: 31.6 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">400 mg every 12 hours: IV: 25.4 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">400 mg every 8 hours: IV: 32.9 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:6em;">C<sub>max </sub>(peak):</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients: 10 mg/kg/dose 3 times daily (multiple dose): IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Neonates and infants: 2.8 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children &lt;2 years of age: 3.6 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 2 to &lt;6 years of age: 2.7 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 6 to &lt;12 years of age: 2 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">Adults (multiple dose):</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg twice daily: Oral: 2.97 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">750 mg twice daily: Oral: 3.59 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">400 mg every 12 hours: IV: 4.56 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">400 mg every 8 hours: IV: 4.07 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Bacterial killing continues after ciprofloxacin concentration falls below the MIC of targeted pathogen and varies based on the organism; generally, 1.5 to 3 hours (Craig 1991; Fuursted 1987; Kumar 1992).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961927"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bactall | Ciplox | Ciprobay | Ciprofloxacin | Ciprolon | Cipropharm | Ciprox | Neocipro | Omacip | Sarf | Xarocen</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Argeflox | Biotic pharma | Cipro | Ciprofloxacina | Ciprofloxacina fabra | Ciprofloxacina hlb | Ciprofloxacina Lazar | Ciprofloxacina northia | Ciprofloxacina richet | Ciprofloxacina sant gall | Ciprofloxacina surar pharma | Ciprofloxacina Vannier | Ciprotenk | Ciprotenk gyno | Cirflox-g | Ciriax | Exertial | Fada ciprofloxacin | Fada Ciprofloxacin | Nexofloxacin | Novidat | Ocefax | Septicide | Septocort | Solucion ciprofloxacina jayor | Xipromox</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin Actavis | Ciprofloxacin arcana | Ciprofloxacin hikma | Ciprofloxacin Kabi | Ciprofloxacin mayrhofer | Ciprofloxacin sandoz | Ciproxin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aspen ciprofloxacin | C flox | Cifran | Ciprofloxacin | Ciprofloxacin alphapharm | Ciprofloxacin bw | Ciprofloxacin-bc | Ciprol | Ciproxin | Genrx ciprofloxacin | Profloxin | Proquin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Amiflox | Aprocin | Bactin | Beuflox | Cecip | Cero | Ciflox | Ciplon | Ciprin | Cipro-a | Cipro-s | Ciprocin | Ciprol | Ciprolex | Ciprolyn | Cipron | Ciprosid | Ciprotec | Ciprox | Ciprozid | Civox | D floxin | Deflox | Doquin | Dumaflox | Efloxin | Flontin | Floxabid | Floxacin | Floxitab | Geflox | Gefloxin | Hiflox | Isofloxin | Kapron | Libracin | Lox | Maprocin | Monipro | Neofloxin | Octabid | Orcipro | Oxpro | Peoflox | Quinocin | Quinox | Tyflox | Uniflox | Xbac | Xefloxin | Xirocip</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacine | Ciprofloxacine EG | Ciprofloxacine fresenius kabi | Ciprofloxacine teva | Ciproxine</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Bactiflox | Cetraxal | Ciprodac | Ciprofloxacin sandoz | Ciprofloxacine | Ciprofloxacine tm | Ciprofloxacine ubigen | Cipronat | Ciprozed | Danciflox | Flocip | Floxin | Philco cipro | Proxacin | Tyflox</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ciphin | Ciprinol | Ciprobay | Ciproflav | Ciprox | Citeral</span>;</li>
<li>
<span class="countryCode">(BO)</span> <span class="country">Bolivia, Plurinational State of</span><span class="countrySeparator">: </span><span class="drugName">Ciproxacin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bactoflox | Cifloxatil | Cifloxtron | Cipro | Ciprobacter | Ciprobiot | Ciprocina | Ciprodine | Ciproflan | Ciproflox | Ciprofloxacina | Ciprofloxacino | Ciprofloxan | Ciprofloxil | Cipromizin | Ciproxan | Ciproxen | Cloridrato de ciprofloxacino | Flobac | Floxen | Fresoflox | Hifloxan | Hypoflox | Quiflox | Quinoflox</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin baxter | Ciprofloxacin fresenius | Ciprofloxacin labatec | Ciprofloxacin Mepha | Ciprofloxacin sandoz | Ciprofloxacin Teva | Ciproxin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Cipro care | Ciprofloxacine kabi | Cipronat | Ciproveine | Neocipro | Sepcen</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Baycip | Cifloxin | Ciproval | Grifociprox</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bei si te | Ben ke | Cifran | Ciplox | Ciprobay | Ciprofloxacin | Hua yu | Huan fu xing | Lin qing | Medociprin | Sai ke xing | Temaril</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Antox | Benemid | Bioquiflox | Cedfox | Cifloblas | Cifloxin | Cimoxen | Cipro | Ciprobac | Ciprodan | Ciprofloxacina | Ciprofloxacino | Ciproquin | Ciprosher | Ciriax | Giraprox | Loxan | Medegol | Megecol | Microbac | Nircip | Quinopron | Sinofar | Sinopen | Tritonex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ciphin | Ciplox | Ciprinol | Ciprobay | Ciprofloxacin Kabi | Ciprofloxacin Teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ciprobay | Ciprofloxacin | Ciprofloxacin Actavis | Ciprofloxacin Claris | Ciprofloxacin Hikma | Ciprofloxacin ibisqus | Ciprofloxacin Kabi | Ciprofloxacin Lyomark | Ciprofloxacin normon | Ciprofloxacin Teva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Amplibiotic | Cifran | Cipro xr | Ciproalfa | Ciprobiotic | Ciprocap | Ciprofel | Ciproflox | Ciprofloxacina | Ciprofloxacina wemed | Ciprofloxacino | Ciprofur-F | Ciproglen | Ciproquin | Ciproquinol | Ciproxina | Ciriax | Dalurox | Eni | Estecina | Flugram | Fraproxina | Inacip | Neocip | Nor-Ciprox | Quinolide | Sepcen | Superflox | Xypranox il</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ciflex | Ciflobac | Cifloxin | Cimaxx | Ciprecu | Ciprofloxacina | Ciprofloxacino | Ciprokron | Cipromedica | Cipronordika | Ciproval | Ciproxan | Ciproxina | Ciriax | Grifociprox | Italprodin | Orquiflox | Osmoflox | Plenolyt | Proflox | Protenil | Septicide | Unex | Zicon</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bactiflox | Cifloxinal | Ciplox | Ciprinol | Ciprobid | Ciprofloxacin | Ciprofloxacin Claris | Ciprofloxacin norameda | Ciprofloxacin sandoz | Ciproxin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Arabcofloroquin | Biofloxidine | Ciprinol | Ciprocin | Ciprocinoro | Ciprofar | Ciprofloxacin | Ciprolkan | Ciproriv | Ciprotak | Ciproxil | Mifoxin | Rancif | Rocinomex | Serviflox | Ultracipro</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Baycip | Catex | Ceprimax | Cetraxal | Ciprofloxacina lasa | Ciprofloxacino | Ciprofloxacino Anages | Ciprofloxacino bayvit | Ciprofloxacino edgen | Ciprofloxacino Fresenius Kabi | Ciprofloxacino grapa | Ciprofloxacino juventus | Ciprofloxacino kabi | Ciprofloxacino kern | Ciprofloxacino Kern pharma | Ciprofloxacino lareq | Ciprofloxacino merck | Ciprofloxacino Normon | Ciprofloxacino tau | Ciprofloxacino ur | Ciprofloxacino vir | Doriman | Estecina | Felixene | Globuce | Huberdoxina | Inkamil | Quipro | Rigoran | Sepcen | Tam | Velmonit</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Asflox | Brucipro | Cipro-a | Ciprobay | Ciprofloxacin | Ciprofloxacin HCL | Ciprofloxacine | Ciprolaks | Cipromax | Ciproxin | Floxin | Sarf</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin Acs Dobfar Generics | Ciprofloxacin baxter | Ciprofloxacin Fresenius Kabi | Ciprofloxacin navamedic | Ciprofloxacin villerton | Ciproxin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ciflox | Ciprofloxacine Aguettant | Ciprofloxacine kabi | Ciprofloxacine macopharma | Ciprofloxacine teva | Ciprofloxacine Winthrop | Uniflox</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin | Ciprofloxacin Teva | Ciproxin</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Bexfloxin | Ciprokin | Ciprolem | O cip</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aristin c | Balepton | Biocipro | Ciprocton | Ciprofal | Ciprofloxacin | Ciprofloxacin/baxter | Ciprofloxacin/kabi | Ciprofloxacin/mylan | Ciprofloxacin/teva | Ciprofloxacin/Vianex | Ciprovian | Ciproxin | Flociprin | Grenis cipro | Infectina | Labentrol | Ladinin | Nafloxin | Revionorm | Topistin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ciplox | Ciprofloxacin | Ciprofloxacin hameln | Ciprox | Ciproxin | Cobay | Cyrocin | Gonning | Loxin | Uroxin | Vesprocin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ciprinol | Ciprofloksacin Lek | Ciprofloxacin Kabi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cifloxin | Cifran | Ciprinol | Ciprobay | Ciprofloxacin Kabi | Ciprofloxacin-Human</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Baquinor | Bernoflox | Bidiprox | Ciflos | Ciprobiotic | Ciprofloxacin | Civell | Corsacin | Cylowam | Disfabac | Etacin | Floxbio | Floxid | Floxifar | Floxigra | Hexiquin | Inciflox | Interflox | Jayacin | Kifarox | Lapiflox | Licoprox | Mecoquin | Mensipox | Miraflox | Phaproxin | Poncoflox | Qilaflox | Quidex | Quinobiotic | Ramavex | Renator | Rexida | Rindoflox | Sarf | Scanax | Tequinol | Volinol | Zeniflox | Zumaflox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cifox | Ciprofloxacin | Ciprofloxacin Claris | Ciproxin | Truoxin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ciplox | Ciprodex | Ciprofloxacin teva | Ciprogis | Ciproxin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Abact | Adcip | Alcipro | Alquin | Aquipro | Arpicip | Axacip | Bc-flox | Bio cipron | Biocip | C Flox | C flox | Canon | Careflox | Cebran | Ceepro | Cefobac | Celo | Celox | Ceprolen | Cetoz | Cft | Cfx | Cifomed | Cifran | Cifran od | Cifrodis | Cimi | Cipad | Cipflacin | Cipiquin | Ciplex | Ciplox | Ciplox od | Ciporal | Cipoxcin | Cipract | Cipret | Cipride | Cipro | Ciproace | Ciprobid | Ciprobiotic | Ciprocore | Ciprodac | Ciproday | Ciprodex | Ciprofloxacin | Ciprofloxacin HCL | Ciprofloxacin usp | Ciproglen | Ciprogold | Ciprojet | Ciprolet | Ciproloc | Ciprolup | Cipromac | Cipromycetin | Cipron | Cipronate | Ciproplus | Ciproquin | Ciprose | Ciprosol | Ciprostan | Ciprosyn | Ciprotas | Ciprotech | Ciprova | Ciprowin | Ciprox | Ciprozen-f | Ciprozol | Cipsol | Ciptab | Ciptec | Cipzy | Ciral | Coflox | Conflox | Corpath | Cosflox | Coutim | Cpf | Disquin | Ecoflox | Encip | Erabact | Fancip | Flocy | Flotox | Floxip | Fresoflox | Gyrolone | Icip | Kwalicip | Loxy | Mencip | Microflox | Mitycip | Neocip | Nt bec | Oracip | Orpic | Ozocip | Penquin | Probid | Prox | Proxar | Quin-c | Quincy | Quinmec | Quinobact | Quintor | Rebect | Recocif | Sanipro | Seflox | Siricipro | Swiflox | Syran | Ultraflox | Unicip | Uniflox | Unocip | Vikcip | Xipro | Zipcin | Zoxan</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin | Ciprofloxacin awa | Ciproneer | Ciprosam</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacina | Ciprofloxacina abc | Ciprofloxacina Acs Dobfar | Ciprofloxacina Bioindustria | Ciprofloxacina hikma | Ciprofloxacina ibigen | Ciprofloxacina keironpharma | Ciprofloxacina myl | Ciprofloxacina Sandoz | Ciproxin | Flontalexin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Bactall | Cefloxine | Cipro | Ciprobay | Ciprodar | Ciproflacin | Ciprolon | Cipromid | Cipropharm | Ciproquin | Floroxin | Mecado sr | Rivroxin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin | Ciproxan | Ciproxan bayer yakuhin | Ciproxan meiji</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aarciflox | Asflox | Axacip | Bruflox | Cachlox | Ceepro | Cifin | Cifran | Cifran od | Cifrotil | Cipcina | Cipex | Ciprobay | Ciprobiotic | Ciprocip | Ciprodac | Ciprodeal | Ciprofloxacin | Ciprofred | Ciprointa | Ciprokant | Ciproken | Ciproquin | Ciproriv | Ciprost | Ciprox | Ciprozed | G ciprox | Galcipro | Ificipro | Ladinin | Megaflox | Neocip | Neocipro | Nircip | Proflax | Proxacin | Roxin | Shalcip | Strox | Ulcip | Ultraflox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aciren | Aju ciprofloxacin | Cf | Ciploxacin | Ciploxcin | Ciplus | Cipmaxin | Cipoxin | Cipro | Ciprobay | Ciprofloxacin | Ciprofloxacin samsung | Ciprouro cr | Ciprox | Ciproxacin | Ciproxin | Cirog | Cirok | Citopcin | Cycin | Cyprox | Daihan ciprofloxacin | Eprosin | Euflox | Floxin | Lofusin | Lopsin | Newloxacin | Pharmgen ciprofloxacin | Qupron | Reyon cifloxacin | Siroxa | Ufexil | Uniciproxacin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ciprobay | Ciproflox | Cipromax | Emicipro | Neocipro | Sarf</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cefloxine | Ciprobay | Ciprocin | Ciprodar | Ciprofloxacine panpharma | Ciprolon | Cipromid | Cipropharm | Ciprox | Estecina | Floxy | Kinoxin | Ladinin | Sepcen | Superflox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ciflozyn | Cifran | Ciphin | Ciplox | Ciprinol | Ciprobay | Ciprocynal | Ciprofloxacin | Ciprofloxacin Claris | Ciprofloxacin norameda | Ciprolet | Cipronat | Ciprova | Lyproquinum | Siflox</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ciproxine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ciflozyn | Cifran | Ciphin | Ciplox | Ciprinol | Ciprobay | Ciprocynal | Ciprofloxacin | Ciprofloxacin Claris | Ciprofloxacin norameda | Ciprolet | Cipronat | Ciprosan | Ciprosol | Ciprova | Lyproquinum | Siflox</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Aflox | Catex | Cipro lp | Ciprofloxacin normon | Ciproxine | Giroflox | Megaflox | Mexine | Spectrum</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Antimed | Apoflox | Arfloxina | Bacproin | Bioflox | Brubiol | Ci-Son's | Ciamsa | Cimogal | Ciprain | Ciprobac | Ciproflox | Ciproflox dm | Ciprofloxac gi | Ciprofloxac.gi ken | Ciprofloxaci.gi le | Ciprofloxacin | Ciprofloxacina | Ciprofloxacina g.i | Ciprofloxacina jayor | Ciprofloxacino | Ciprofloxacino gi | Ciprofloxacino Innovare | Ciprofur | Ciprohexal | Ciproser | Ciproxina | Ciqfadin | Ciriax | Clortory | Deixedol | Dinaflox | Eni | Flovin | Floxager | Floxantina | Flubindo | Fluorquin | Fluxacord | Genoflox | Infloxa | Italnik | Kenzoflex | Lemyflox | Liferxina | Loxaniflin | Microrgan | Mitroken | Mitroken i | Novoquin | Patox | Profluxol | Proxitec I | Quinoflox | Suiflox | Trigen | Trigen-p | Vifloxina | Wasiprobil | Z-xin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ceflox | Cifloxin | Cifran | Ciprinol | Ciprobay | Ciproflo | Ciproglen | Ciprox | Ciproxol | Ificipro | Quintor</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ac ciproflo | Acipro | Agecipro | Badiproxin | Bari ciprofloxacin | Bflaxin | Bg klycxin | Bioraj ciprofloxacin | Cenox | Cifga | Ciflaxin | Ciflomax | Cinnamon ciprofloxacin | Cipmed | Cipocil | Cipro mon | Ciprobact | Ciprobon | Ciprodivine | Ciprodon | Ciprofloxacin | Ciprofloxacin marcolivia | Ciprofloxacin marcson | Ciprogyl | Ciprokris | Ciprolem | Cipronow | Ciproriv | Ciprosure | Ciprotab | Ciproven | Ciproxact | Ciprozap | Cisepro | Danciflox | Dxtproxin | Elcip | Floxipro | Guciprox | Interflox | Joyfad ciprofloxacin | Juproxcin | Kambid | Kinglion ciprofloxacin | Lodiflox | Lyncipro | Maco ciprofloxacin | Ocipro | Ogfloxx | Ozila ciprofloxacin | Pharmamax ciprofloxacin | Pharmaniaga ciprofloxacin | Rapidflox | Rcpro | Rebocip | Rgi cipro | Ricnos ciprofloxacin | Rumaxine | Samxacine | Sd ciprofloxacin | Seebest ciprofloxacin | Shinfield ciprofloxacin | Simbflox | Siprosan | Softhealth ciprofloxacin | St dennis ciprofloxacin | Stericin | Sukaprot | Sunycip | Talibex ciprofloxacin | Tinsipro | Trexip | Ultraflox | Unicure ciprofloxacin | Uniflox | Uwacipro | Vitaprocin | Wincip | Zipo | Zoopro</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacine | Ciprofloxacine Actavis | Ciprofloxacine Hikma | Ciprofloxacine kabi | Ciprofloxacine Mylan | Ciprofloxacine PCH | Ciprofloxacine Ratiopharm | Ciproxin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin | Ciprofloxacin Acs Dobfar Generics | Ciprofloxacin baxter | Ciprofloxacin Claris | Ciprofloxacin Hospira | Ciprofloxacin mayne | Ciprofloxacin navamedic | Ciprofloxacin ratiopharm | Ciproxin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cipflox | Ciprofloxacin | Ciprofloxacine mylan | Ciproxin</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Omacip</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alcipro | C flox | Ciflix | Cifloxdan | Cifran | Cinaflox | Ciprobac | Ciprocalmex | Ciprof-200 | Ciprofloxacino | Ciprofloxacino 500mg | Ciprofur-F | Ciprolin | Cipronor | Cipropharma | Ciproquin | Ciprox | Ciproxacol | Ciproxan | Ciproxina | Ciriax | Cistimicina | Espitacin | Ificipro | Nircip | Novoxacil | Onicax | Osmoflox | Quinocip | Quinopron</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acipro | Axacip | Bacipro | Bacpro | Bactiflox | Baxolyn | Ciclodin | Cidrolex | Cidroxal | Ciflobid | Ciflodal | Ciflomed | Cifloxin | Cipcor | Cipfast | Ciplife | Cipro base | Ciprobay | Ciprobiotic | Ciprodan | Ciprodin | Ciprofen | Ciproflox | Ciprofloxacin sandoz | Ciprokab | Ciprolite | Cipromac | Cipromet | Ciprosan | Ciproted | Ciprotor | Ciproven | Ciproxel | Ciprozan | Ciprozef | Ciptid | Cipulox | Cirok | Cobay | Cyclor | Cyfrox | Flaxid | Floxil | Goflox v | Holdestin | Inoxzel | Iprolan | Kinogen | Kinoves | Laitun | Ocxan | Orpic | Probact | Prolon | Prozin | Quidex | Quilox | Quinocip | Quiprime | Rapiqure | Rexfobys | Roflox | Sigmacip | Uticin | Vexcipro | Xipro | Xyprody | Yokocip | Zalvos | Zipro | Ziprox | Zunexan | Zyflox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">A cip | Adcipro | Affif | Alacep | Alencip | Amesure | Amity | Aristin c | Astilcip | Aultocip | Axocip | Bacip | Becip | Biocip | C flox | C oxacin | Catex | Cflox | Cibo | Cilara | Ciloxon | Cinoflox | Cinoxin | Cinrol | Cipak | Cipaur | Cipesta | Cipesta xr | Ciplox | Cipmed | Cipol | Ciponor | Ciporains | Ciposim | Cipotent | Ciprexis | Ciprexis ds | Ciprin | Ciprobact | Ciprobest | Ciprocide | Ciprofast | Ciprofaz | Ciprofed | Ciprofena | Ciprolis | Ciprolite | Cipromir | Cipropar | Ciproquine | Ciprorel | Ciprosafe | Ciprose | Ciprovac | Ciprovid | Ciprovin | Ciprox | Ciprozan | Ciprozee sr | Cipsa | Cipson | Ciptec | Cipton | Cipvax xr | Cipwel | Civox | Ckflox | Cpzaf | Cronacip | Curabid | Cycin | Cygnet | Cyrocin | Cyto | Danpro | Decip | Dicip | Efecip | Efsan | Euro | Excipro | Faascip | Fepro floxacine | Finch | Floxacin | Fobin | Foxirex | Gavel | Gee cipro | Gen cipro | Gloxinia | Harflox | Harod | Hemel | Hi cip | Hiflox | Hipro xr | Hitroxin | Infecnil | Inoquin | Irzacip | Jasflox | Jawaflox | Jexin | Labetrol | Lamcit | Lucid | M cip | Medicip | Megaflox | Mercip | Metein | Mytil | Nafcin | Neofloxin | Nexcip | Nicil | Nik | Novaedaxin | Novidat | Ntbact | Orpic | Percip | Polygard | Proflox | Proloxab | Quash | Qucin | Quinocin | Quinoflox | Qupron | Radiflox | Relcip | Renflox | Ringacip | Rocip | Roxin | Saicip | Savoxacin | Secofloxacin | Sipro | Siprof | Siroxin | Sn cip | Solo cip | Strox | Ume cip | Uzaril | Veprox | Vift | Viloc | Vorcin | Wincip | Winflox | Xocip | Yokocip | Z cipro | Zeproquin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ciprobay | Ciprofloxacin | Ciprofloxacin Claris | Ciprofloxacin Kabi | Cipronex | Cipropol | Proxacin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cipro | Ciprofloxacin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacina | Ciprofloxacina claris | Ciprofloxacina generis | Ciprofloxacina hikma | Ciprofloxacina kabi | Ciprofloxacina labesfal | Ciprofloxacina tecnimede | Ciprofloxacina teva | Ciproquinol | Ciproxina | Estecina | Giroflox | Megaflox | Nivoflox | Quinox</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acid 200 | Acid 400 | Cipro | Ciprofloxacina | Ciprofloxacina bergamo | Ciprofloxacina genfar | Ciprofloxacina millet | Ciprofloxacina mintlab | Ciprofloxacina northia | Ciprofloxacina p.a.n. | Ciprofloxacina prosalud | Ciprofloxacino quimfa | Ciproval | Dibactil | Neoxetic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Bactall | Bactiflox Neo | Ciflosin | Ciflox | Cipro | Cipro-Sol | Ciprobay | Ciprobay IV | Ciprocin | Ciprodar | Ciprodar XL | Ciprofar | Ciproflacin | Ciproflox | Ciprogen | CiproHEXAL | Ciprolet | Ciprolife | Ciprolon | Ciprolon IV | Cipromax | Cipromid | Cipropharm | Ciproquin | Ciprox IV | Ciproxen | Emicipro | Floroxin | Floxacin | Floxip | Neocipro | Omacip | Quinox (Tabuk) | Sarf</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aristin c | Ciprinol | Ciprofloxacina | Ciprofloxacina infomed | Ciprolet | Grenis cipro | Ufexil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alcipro | Aquacipro | Bacigen | Basidjen | Cefobac | Ceprova | Ciflox alium | Ciflozyn | Cifran | Ciplox | Ciprinol | Ciprobay | Ciprobid | Ciprocynal | Ciprofloxabol | Ciprofloxacin | Ciprofloxacin sandoz | Ciprolacare | Ciprolet | Cipronat | Ciproquin | Ciprosan | Ciprosol | Ciprovin | Cybrobid | Cypronate | Ificipro | Lyproquinum | Microfloxum | Procipro | Quintor | Siflox | Vero ciprofloxacin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bactall | Ciflox | Cifogru | Ciprobay | Ciprocare | Ciprocin | Ciproflox | Ciprolon | Pms-ciprofloxacin | Quinox</span>;</li>
<li>
<span class="countryCode">(SD)</span> <span class="country">Sudan</span><span class="countrySeparator">: </span><span class="drugName">Amiciprox</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin Fresenius Kabi | Ciprofloxacin Hospira | Ciprofloxacin villerton | Ciproxin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ciprobay | Ciprofloxacin | Cirok | Cycin | Topistin | Uroxin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ciprinol | Ciprum</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ciphin | Ciplox | Ciprinol | Ciprobay | Ciprofloxacin Kabi | Ciprolon</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Ciprofit | Ciprofloxacin | Roncip</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cifloxin | Cifolox | Cifran | Cifrotil | Cilab | Cipracin | Ciprobay | Ciprobid | Ciprofloxacin | Ciprom m | Ciprom-h | Ciproquin | Ciprovid | Ificipro | Q bact | Ultraflox</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ciproflo info | Ciproject | Sifloks</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ciflosin | Cipro | Ciprocam | Ciprokabi | Ciproktan | Ciprolaks | Cipronatin | Cipropol | Ciproxin | Flotic | Loxasid | Novarex | Roxin | Selfleks ciprasel | Siproject | Ufexil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ciflogen | Cinolone | Cipocin | Ciproflo | Ciprofloxacin | Ciproxin | Cixa | Proxacin | Seforce | Xacine</span>;</li>
<li>
<span class="countryCode">(TZ)</span> <span class="country">Tanzania, United Republic of</span><span class="countrySeparator">: </span><span class="drugName">Diocipro</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cefobac | Ciflox | Cifran | Cifrel | Ciprinol | Ciprobay | Ciprobid | Ciprocin n | Ciprocor | Ciprocynal | Ciprofloxacin | Ciprofloxacinum | Ciprolet | Ciprom | Cipronat | Cipropan | Ciprosan | Ificipro</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Aarciflox | Axacip | Ceepro | Cifin | Ciprofloxacin | Ciprofloxacin uf | Ciprol | Ciproren | Ciprox | Ecoflox | Eurocip | Ificipro | Ladinin | Nircip</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Blader | Blanflax | C Flox | Ciapar | Cifloxtron | Cipro | Ciprocid | Ciprofloxacina | Ciprofloxacina Lazar | Ciproxina | Ciriax | Cisterak | Fada Ciprofloxacin | Fresoflox | Novidat | Ocefax | Septicide</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bacipro | Baflox | Cifran | Ciprivax | Ciproalfa | Ciproflox | Ciprofloxacina | Ciprofloxacina lactato | Ciprolet | Ciproquin | Ciprotan | Ciproxina | Wellcip | Zolina</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agicipro | Basmicin | Ciforkid | Ciprofloxacin Kabi | Dophacipro | Dumver</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen ciprofloxacin | Ciprobay | Ciprocina | Ciprofloxacin fresenius | Ciprofloxacin safeline | Loxip | Sabax ciprofloxacin | Spec topistin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Alcipro | Cerocip | Ciflox | Ciplox | Ciplox iv | Ciprodac | Ciprofloxacin | Ciproglen | Ciprokant | Cipronat | Ciproplus | Ciproquin | Ciptid | Ecoflox | Lyproquin | Procip | Q bact | Rancip | Recipro | Shalcip | Strox | Xiprox</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Ciprobay | Ciprovar | Microflox</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31487382">
<a name="31487382"></a>Abbott L, Plummer A, Hoo ZH, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. <i>Cochrane Database Syst Rev</i>. 2019;9(9):CD006682. doi:10.1002/14651858.CD006682.pub6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31487382/pubmed" id="31487382" target="_blank">31487382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med.</i> 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24428853">
<a name="24428853"></a>Abo-Salem E, Fowler JC, Attari M, et al. Antibiotic-induced cardiac arrhythmias. <i>Cardiovasc Ther</i>. 2014;32(1):19‐25. doi:10.1111/1755-5922.12054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24428853/pubmed" id="24428853" target="_blank">24428853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21785119">
<a name="21785119"></a>Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. <i>Arch Dis Child</i>. 2011;96(9):874-880. doi:10.1136/adc.2010.208843<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21785119/pubmed" id="21785119" target="_blank">21785119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15523125">
<a name="15523125"></a>Aggarwal P, Dutta S, Garg SK, et al. Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. <i>Indian Pediatr</i>. 2004;41(10):1001-1007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15523125/pubmed" id="15523125" target="_blank">15523125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Agha.1">
<a name="Agha.1"></a>Agha R, Goldberg MB. Shigella infection: Treatment and prevention in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33067334">
<a name="33067334"></a>Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. <i>Gut</i>. 2021;70(1):9-29. doi:10.1136/gutjnl-2020-321790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/33067334/pubmed" id="33067334" target="_blank">33067334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24472364">
<a name="24472364"></a>Ali AK. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. <i>Ann Epidemiol</i>. 2014;24(4):279‐285. doi:10.1016/j.annepidem.2013.12.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24472364/pubmed" id="24472364" target="_blank">24472364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23585504">
<a name="23585504"></a>Ali WH. Ciprofloxacin-associated posterior reversible encephalopathy. <i>BMJ Case Rep</i>. 2013;2013:bcr2013008636. doi:10.1136/bcr-2013-008636<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23585504/pubmed" id="23585504" target="_blank">23585504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24340128">
<a name="24340128"></a>Alkhateeb H, Said S, Cooper CJ, Gaur S, Porres-Aguilar M. DRESS syndrome following ciprofloxacin exposure: An unusual association. <i>Am J Case Rep</i>. 2013;14:526‐528. doi:10.12659/AJCR.889703<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24340128/pubmed" id="24340128" target="_blank">24340128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12022900">
<a name="12022900"></a>Allan DS, Thompson CM, Barr RM, Clark WF, Chin-Yee IH. Ciprofloxacin-associated hemolytic-uremic syndrome. <i>Ann Pharmacother</i>. 2002;36(6):1000‐1002. doi:10.1345/aph.1A350<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12022900/pubmed" id="12022900" target="_blank">12022900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352180">
<a name="24352180"></a>Alshammari TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, LaPlante KL. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. <i>Am J Health Syst Pharm</i>. 2014;71(1):37-43. doi:10.2146/ajhp130165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24352180/pubmed" id="24352180" target="_blank">24352180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics (AAP) Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610. doi:10.1542/peds.2011-1330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Anderson.1">
<a name="Anderson.1"></a>Anderson DJ, Sexton DJ. Antimicrobial prophylaxis for prevention of surgical site infection in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Andrews.1">
<a name="Andrews.1"></a>Andrews J, John, J, Charles, RC. Enteric (typhoid and paratyphoid) fever: Treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelsons.1">
<a name="Nelsons.1"></a>Antimicrobial therapy according to clinical syndromes. In: Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26393387">
<a name="26393387"></a>Arabyat RM, Raisch DW, McKoy JM, Bennett CL. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. <i>Expert Opin Drug Saf</i>. 2015;14(11):1653‐1660. doi:10.1517/14740338.2015.1085968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26393387/pubmed" id="26393387" target="_blank">26393387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 66.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36009990">
<a name="36009990"></a>Autore G, Bernardi L, La Scola C, et al. Management of pediatric urinary tract infections: a Delphi study. <i>Antibiotics (Basel)</i>. 2022;11(8):1122. doi:10.3390/antibiotics11081122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/36009990/pubmed" id="36009990" target="_blank">36009990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.1">
<a name="Berbari.1"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.1">
<a name="Baddour.1"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 20, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2">
<a name="Baddour.2"></a>Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36043414">
<a name="36043414"></a>Baddour LM, Weimer MB, Wurcel AG, et al; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease. Management of infective endocarditis in people who inject drugs: a scientific statement from the American Heart Association. <i>Circulation</i>. 2022;146(14):e187-e201. doi:10.1161/CIR.0000000000001090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/36043414/pubmed" id="36043414" target="_blank">36043414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12. doi:10.1542/pir.2017-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22615289">
<a name="22615289"></a>Barnhill AE, Brewer MT, Carlson SA. Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. <i>Antimicrob Agents Chemother</i>. 2012;56(8):4046‐4051. doi:10.1128/AAC.00678-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22615289/pubmed" id="22615289" target="_blank">22615289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.1">
<a name="Barshak.1"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1978050">
<a name="1978050"></a>Bates CJ, Wilcox MH, Spencer RC, Harris DM. Ciprofloxacin and <i>Clostridium difficile</i> infection. <i>Lancet</i>. 1990;336(8724):1193. doi:10.1016/0140-6736(90)92808-u<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1978050/pubmed" id="1978050" target="_blank">1978050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Beckwith.1">
<a name="Beckwith.1"></a>Beckwith MC, Feddema SS, Barton RG, Graves C. A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods. <i>Hosp Pharm</i>. 2004;39(3):225-237.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31333137">
<a name="31333137"></a>Benlice C, Shen B, Steele SR. Prevention and medical treatment of pouchitis in ulcerative colitis. <i>Curr Drug Targets</i>. 2019;20(13):1399-1408. doi:10.2174/1389450120666190723130137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31333137/pubmed" id="31333137" target="_blank">31333137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31500468">
<a name="31500468"></a>Bennett AC, Bennett CL, Witherspoon BJ, Knopf KB. An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency. <i>Expert Opin Drug Saf</i>. 2019;18(11):1055‐1063. doi:10.1080/14740338.2019.1665022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31500468/pubmed" id="31500468" target="_blank">31500468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46. doi:10.1093/cid/civ482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16153261">
<a name="16153261"></a>Berdal JE, Skråmm I, Mowinckel P, et al. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections.<i> Clin Microbiol Infect.</i> 2005;11(10):843-845. doi: 10.1111/j.1469-0691.2005.01230.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16153261/pubmed" id="16153261" target="_blank">16153261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31078137">
<a name="31078137"></a>Berhe A, Russom M, Bahran F, Hagos G. Ciprofloxacin and risk of hypoglycemia in non-diabetic patients. <i>J Med Case Rep</i>. 2019;13(1):142. doi:10.1186/s13256-019-2083-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31078137/pubmed" id="31078137" target="_blank">31078137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27138564">
<a name="27138564"></a>Bidell MR, Lodise TP. Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk? <i>Pharmacotherapy</i>. 2016;36(6):679‐693. doi:10.1002/phar.1761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/27138564/pubmed" id="27138564" target="_blank">27138564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26926640">
<a name="26926640"></a>Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and third-generation-cephalosporin resistance among hospitalized patients with urinary tract infections due to Escherichia coli: do rates vary by hospital characteristics and geographic region? <i>Antimicrob Agents Chemother</i>. 2016;60(5):3170-3173. doi:10.1128/AAC.02505-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26926640/pubmed" id="26926640" target="_blank">26926640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi: 10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30811525">
<a name="30811525"></a>Bisaccia DR, Aicale R, Tarantino D, Peretti GM, Maffulli N. Biological and chemical changes in fluoroquinolone-associated tendinopathies: a systematic review. <i>Br Med Bull</i>. 2019;130(1):39‐49. doi:10.1093/bmb/ldz006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30811525/pubmed" id="30811525" target="_blank">30811525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bitton.1">
<a name="Bitton.1"></a>Bitton A, Fichera A. Perianal Crohn’s disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3116917">
<a name="3116917"></a>Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. <i>Antimicrob Agents Chemother.</i> 1987;31(7):1054-1060. doi:10.1128/aac.31.7.1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/3116917/pubmed" id="3116917" target="_blank">3116917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15677845">
<a name="15677845"></a>Bossi P, Tegnell A, Baka A, et al; Taskforce on Bioterrorism (BICHAT), Public Health Directorate, European Commission, Luxembourg. BICHAT guidelines for the clinical management of tularemia and bioterrorism-related tularemia. <i>Euro Surveill</i>. 2004;9(12):E9-E10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15677845/pubmed" id="15677845" target="_blank">15677845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834290">
<a name="31834290"></a>Bower WA, Schiffer J, Atmar RL, et al; CDC ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. <i>MMWR Recomm Rep</i>. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31834290/pubmed" id="31834290" target="_blank">31834290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2011a;53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelsons.2">
<a name="Nelsons.2"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777226">
<a name="24777226"></a>Bradley JS, Peacock G, Krug SE, et al; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-e1436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24777226/pubmed" id="24777226" target="_blank">24777226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society of Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326-2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1976960">
<a name="1976960"></a>Cain DB, O'Connor ME. Pseudomembranous colitis associated with ciprofloxacin. <i>Lancet</i>. 1990;336(8720):946. doi:10.1016/0140-6736(90)92320-h<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1976960/pubmed" id="1976960" target="_blank">1976960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16297731">
<a name="16297731"></a>Calhoun JH, Manring MM. Adult osteomyelitis. <i>Infect Dis Clin North Am</i>. 2005;19(4):765-786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16297731/pubmed" id="16297731" target="_blank">16297731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3292209">
<a name="3292209"></a>Campoli-Richards DM, Monk JP, Price A, et al. Ciprofloxacin. A Review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use. <i>Drugs</i>. 1988;35(4):373-447.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/3292209/pubmed" id="3292209" target="_blank">3292209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.4">
<a name="CDC.4"></a>Centers for Disease Control and Prevention. Antibiotic treatment. Recommendations for the use of antibiotics for the treatment of cholera. <a href="https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html" target="_blank">https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html</a>. Updated June 1, 2022a. Accessed October 26, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention. Plague. Resources for clinicians. <a href="https://www.cdc.gov/plague/healthcare/clinicians.html#treatment" target="_blank">http://www.cdc.gov/plague/healthcare/clinicians.html#treatment</a>. Updated October 5, 2015a. Accessed June 9, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Centers for Disease Control and Prevention. Plague. Resources for clinicians. <a href="https://www.cdc.gov/plague/healthcare/clinicians.html" target="_blank">https://www.cdc.gov/plague/healthcare/clinicians.html</a>. Last reviewed February 10, 2020. Accessed April 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention. Recommendations for the use of antibiotics for the treatment of cholera: summary recommendations. 2015. <a href="https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html" target="_blank">https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html</a>. Updated January 20, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention. The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2018. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea</a>. Updated June 13, 2017. Accessed September 6, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.5">
<a name="CDC.5"></a>Centers for Disease Control and Prevention. Tularemia. For clinicians. <a href="https://www.cdc.gov/tularemia/clinicians/index.html" target="_blank">https://www.cdc.gov/tularemia/clinicians/index.html</a>. Updated July 5, 2022b. Accessed October 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10987739">
<a name="10987739"></a>Chocarro A, Gonzalez A, Garcia I. Treatment of tularemia with ciprofloxacin. <i>Clin Infect Dis</i>. 2000;31(2):623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10987739/pubmed" id="10987739" target="_blank">10987739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20009146">
<a name="20009146"></a>Cholongitas E, Georgousaki C, Spyrou S, Dasenaki M. Ciprofloxacin-induced acute cholestatic hepatitis. <i>Ann Hepatol</i>. 2009;8(4):400-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/20009146/pubmed" id="20009146" target="_blank">20009146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23948133">
<a name="23948133"></a>Chou HW, Wang JL, Chang CH, Lee JJ, Shau WY, Lai MS. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. <i>Clin Infect Dis</i>. 2013;57(7):971‐980. doi:10.1093/cid/cit439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23948133/pubmed" id="23948133" target="_blank">23948133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112. doi:10.1093/cid/cir1043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431134">
<a name="12431134"></a>Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12431134/pubmed" id="12431134" target="_blank">12431134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cipro.1">
<a name="Cipro.1"></a>Cipro IV (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cipro.2">
<a name="Cipro.2"></a>Cipro tablet and oral suspension (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cipro.3">
<a name="Cipro.3"></a>Cipro oral suspension (ciprofloxacin) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cipro.6">
<a name="Cipro.6"></a>Cipro tablet and oral suspension (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pharmascience.1">
<a name="Pharmascience.1"></a>Ciprofloxacin extended-release tablets [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CiprofloxacinD5W.1">
<a name="CiprofloxacinD5W.1"></a>Ciprofloxacin in D5W [prescribing information]. Lake Forest, IL: Hospira Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.9">
<a name="Generic.9"></a>Ciprofloxacin injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.1">
<a name="Generic.1"></a>Ciprofloxacin injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.2">
<a name="Generic.2"></a>Ciprofloxacin injection [prescribing information]. Lake Forest, IL: Hospira Inc; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.3">
<a name="Generic.3"></a>Ciprofloxacin injection [prescribing information]. North Brunswick, NJ: Claris Lifesciences; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.4">
<a name="Generic.4"></a>Ciprofloxacin injection [prescribing information]. Toronto, Ontario, Canada: Fresenius Kabi Canada Ltd; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.5">
<a name="Generic.5"></a>Ciprofloxacin injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.6">
<a name="Generic.6"></a>Ciprofloxacin injection, solution [prescribing information]. Lake Forest, IL: Hospira Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.7">
<a name="Generic.7"></a>Ciprofloxacin tablet and injection [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.8">
<a name="Generic.8"></a>Ciprofloxacin injection [prescribing information]. Toronto, Ontario, Canada: Fresenius Kabi Canada Ltd; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11793615">
<a name="11793615"></a>Cohen JS. Peripheral neuropathy associated with fluoroquinolones. <i>Ann Pharmacother</i>. 2001;35(12):1540‐1547. doi:10.1345/aph.1Z429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11793615/pubmed" id="11793615" target="_blank">11793615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29290231">
<a name="29290231"></a>Cohen R, Raymond J, Gendrel D. Antimicrobial treatment of diarrhea/acute gastroenteritis in children. <i>Arch Pediatr</i>. 2017;24(12S):S26-S29. doi:10.1016/S0929-693X(17)30515-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29290231/pubmed" id="29290231" target="_blank">29290231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23515099">
<a name="23515099"></a>Cohn AC, MacNeil JR, Clark TA, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2013;62(RR-2):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23515099/pubmed" id="23515099" target="_blank">23515099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26926407">
<a name="26926407"></a>Coker TJ, Dierfeldt DM. Acute bacterial prostatitis: Diagnosis and management. <i>Am Fam Physician</i>. 2016;93(2):114-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26926407/pubmed" id="26926407" target="_blank">26926407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141-1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16951028">
<a name="16951028"></a>Committee on Infectious Diseases. The Use of Systemic Fluoroquinolones. <i>Pediatrics</i>. 2006;118(3):1287-1292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16951028/pubmed" id="16951028" target="_blank">16951028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35073779">
<a name="35073779"></a>Cordova Sanchez A, Chohan M, Olatunde O, White C. A rare case of ciprofloxacin-induced bradycardia recognized by a smartwatch. <i>J Investig Med High Impact Case Rep</i>. 2022;10:23247096211069761. doi:10.1177/23247096211069761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/35073779/pubmed" id="35073779" target="_blank">35073779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2375140">
<a name="2375140"></a>Cover DL, Mueller BA. Ciprofloxacin penetration into human breast milk: a case report. <i>DICP</i>. 1990;24(7-8):703-704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2375140/pubmed" id="2375140" target="_blank">2375140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect. <i>Clin Microbiol Newsletter.</i> 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1325620">
<a name="1325620"></a>Davies SP, Azadian BS, Kox WJ, et al. Pharmacokinetics of Ciprofloxacin and Vancomycin in Patients With Acute Renal Failure Treated by Continuous Haemodialysis. <i>Nephrol Dial Transplant</i>. 1992;7(8):848-854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1325620/pubmed" id="1325620" target="_blank">1325620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21475415">
<a name="21475415"></a>de la Cabada Bauche J, DuPont HL. New Developments in Traveler’s Diarrhea. <i>Gastroenterol Hepatol</i>. 2011;7(2):88-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21475415/pubmed" id="21475415" target="_blank">21475415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11386933">
<a name="11386933"></a>Dennis DT, Inglesby TV, Henderson DA, et al; Working Group on Civilian Biodefense. Tularemia as a biological weapon: medical and public health management. <i>JAMA. </i>2001;285(21):2763-2773.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11386933/pubmed" id="11386933" target="_blank">11386933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30664553">
<a name="30664553"></a>Desai M, Fathallah J, Nutalapati V, Saligram S. Antibiotics versus no antibiotics for acute uncomplicated diverticulitis: a systematic review and meta-analysis. <i>Dis Colon Rectum</i>. 2019;62(8):1005-1012. doi:10.1097/DCR.0000000000001324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30664553/pubmed" id="30664553" target="_blank">30664553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24879980">
<a name="24879980"></a>Devarbhavi H, Andrade RJ. Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. <i>Semin Liver Dis</i>. 2014;34(2):145-161. doi:10.1055/s-0034-1375956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24879980/pubmed" id="24879980" target="_blank">24879980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11990328">
<a name="11990328"></a>Dixit RK, Satapathy SK, Kumar R, et al. Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. <i>Indian J Gastroenterol</i>. 2002;21(2):62-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11990328/pubmed" id="11990328" target="_blank">11990328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8384815">
<a name="8384815"></a>Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of <i>Pseudomonas</i> sepsis. <i>Antimicrob Agents Chemother.</i> 1993;37(3):483-490. doi:10.1128/aac.37.3.483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/8384815/pubmed" id="8384815" target="_blank">8384815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10616701">
<a name="10616701"></a>Dutta TK, Badhe BA. Ciprofloxacin-induced bone marrow depression. <i>Postgrad Med J</i>. 1999;75(887):571-573. doi:10.1136/pgmj.75.887.571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10616701/pubmed" id="10616701" target="_blank">10616701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29511692">
<a name="29511692"></a>Estofan LJF, Naydin S, Gliebus G. Quinolone-induced painful peripheral neuropathy: A case report and literature review. <i>J Investig Med High Impact Case Rep</i>. 2018;6:2324709617752736. doi:10.1177/2324709617752736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29511692/pubmed" id="29511692" target="_blank">29511692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29653741">
<a name="29653741"></a>European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. <i>J Hepatol</i>. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29653741/pubmed" id="29653741" target="_blank">29653741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29157532">
<a name="29157532"></a>Farid S, Mahmood M, Abu Saleh OM, et al. Clinical manifestations and outcomes of fluoroquinolone-related acute interstitial nephritis. <i>Mayo Clin Proc</i>. 2018;93(1):25‐31. doi:10.1016/j.mayocp.2017.08.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29157532/pubmed" id="29157532" target="_blank">29157532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34051983">
<a name="34051983"></a>Feuerstein JD, Ho EY, Shmidt E, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. <i>Gastroenterology</i>. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/34051983/pubmed" id="34051983" target="_blank">34051983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.1">
<a name="File.1"></a>File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). CIPRO (Ciprofloxacin) Use by Pregnant and Lactating Women. <a href="http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130712.htm" target="_blank">http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130712.htm</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8517694">
<a name="8517694"></a>Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. <i>Antimicrob Agents Chemother</i>. 1993;37(5):1073-1081. doi:10.1128/aac.37.5.1073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/8517694/pubmed" id="8517694" target="_blank">8517694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28458435">
<a name="28458435"></a>Foti C, Romita P, Zanframundo G, et al. Ciprofloxacin induced acute generallised exanthematous pustulosis. <i>Indian J Pharmacol</i>. 2017;49(1):119‐120. doi:10.4103/0253-7613.201014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28458435/pubmed" id="28458435" target="_blank">28458435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32364593">
<a name="32364593"></a>Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. <i>JAMA Netw Open</i>. 2020;3(5):e203951. doi:10.1001/jamanetworkopen.2020.3951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/32364593/pubmed" id="32364593" target="_blank">32364593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26425618">
<a name="26425618"></a>Francis JK, Higgins E. Permanent peripheral neuropathy: A case report on a rare but serious debilitating side-effect of fluoroquinolone administration. <i>J Investig Med High Impact Case Rep</i>. 2014;2(3):2324709614545225. doi:10.1177/2324709614545225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26425618/pubmed" id="26425618" target="_blank">26425618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10423464">
<a name="10423464"></a>Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. <i>N Engl J Med</i>. 1999;341(5):305-311. doi:10.1056/NEJM199907293410501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10423464/pubmed" id="10423464" target="_blank">10423464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15856137">
<a name="15856137"></a>Friedl A, Heinzer I, Fankhauser H. Tularemia after a dormouse bite in Switzerland. <i>Eur J Clin Microbiol Infect Dis</i>. 2005;24(5):352-354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15856137/pubmed" id="15856137" target="_blank">15856137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15585448">
<a name="15585448"></a>Friedrich LV, Dougherty R. Fatal Hypoglycemia Associated With Levofloxacin. <i>Pharmacotherapy</i>. 2004;24(12):1807-1812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15585448/pubmed" id="15585448" target="_blank">15585448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2731404">
<a name="2731404"></a>Frost RW, Lettieri JT, Krol G, Shamblen EC, Lasseter KC. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. <i>Clin Pharmacol Ther</i>. 1989;45(6):608-616. doi:10.1038/clpt.1989.81<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2731404/pubmed" id="2731404" target="_blank">2731404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3113938">
<a name="3113938"></a>Fuursted K. Post-antibiotic effect of ciprofloxacin on <i>Pseudomonas aeruginosa</i>. <i>Eur J Clin Microbiol</i>. 1987;6(3):271-274. doi:10.1007/BF02017611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/3113938/pubmed" id="3113938" target="_blank">3113938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32158437">
<a name="32158437"></a>Fuzi M, Rodriguez Baño J, Toth A. Global Evolution of Pathogenic Bacteria With Extensive Use of Fluoroquinolone Agents. <i>Front Microbiol</i>. 2020;11:271. doi:10.3389/fmicb.2020.00271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/32158437/pubmed" id="32158437" target="_blank">32158437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gamboa.1">
<a name="Gamboa.1"></a>Gamboa F, Rivera JM, Gomez Mateos JM, et al. Ciprofloxacin-Induced Henoch-Schönlein Purpura. <i>Ann Pharmacother</i>. 1995;29(1):84.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1563233">
<a name="1563233"></a>Gardner DK, Gabbe SG, Harter C. Simultaneous Concentrations of Ciprofloxacin in Breast Milk and in Serum in Mother and Breast-Fed Infant. <i>Clin Pharm</i>. 1992;11(4):352-354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1563233/pubmed" id="1563233" target="_blank">1563233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19022360">
<a name="19022360"></a>Ge DT, Law PY, Kong SK, Ho YY. Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. <i>Toxicol Lett</i>. 2009;184(2):81-84. doi:10.1016/j.toxlet.2008.10.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19022360/pubmed" id="19022360" target="_blank">19022360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24284031">
<a name="24284031"></a>Ghaly H, Jörns A, Rustenbeck I. Effect of fluoroquinolones on mitochondrial function in pancreatic beta cells. <i>Eur J Pharm Sci</i>. 2014;52:206-214. doi:10.1016/j.ejps.2013.11.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24284031/pubmed" id="24284031" target="_blank">24284031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19073153">
<a name="19073153"></a>Ghaly H, Kriete C, Sahin S, et al. The insulinotropic effect of fluoroquinolones. <i>Biochem Pharmacol</i>. 2009;77(6):1040‐1052. doi:10.1016/j.bcp.2008.11.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19073153/pubmed" id="19073153" target="_blank">19073153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2589353">
<a name="2589353"></a>Giamarellou H, Kolokythas E, Petrikkos G, et al. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida. <i>Am J Med</i>. 1989;87(5A):49S-51S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2589353/pubmed" id="2589353" target="_blank">2589353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GTFCC.1">
<a name="GTFCC.1"></a>Global Task Force on Cholera Control (GTFCC). Cholera outbreak response field manual. https://www.gtfcc.org/wp-content/uploads/2020/04/gtfcc-cholera-outbreak-response-field-manual.pdf. Published October 2019. Accessed September 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1915388">
<a name="1915388"></a>Gogos CA, Maraziotis TG, Papadakis N, Beermann D, Siamplis DK, Bassaris HP. Penetration of ciprofloxacin into human cerebrospinal fluid in patients with inflamed and non-inflamed meninges. <i>Eur J Clin Microbiol Infect Dis</i>. 1991;10(6):511-514. doi:10.1007/BF01963940<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1915388/pubmed" id="1915388" target="_blank">1915388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.2022">
<a name="Goldenberg.2022"></a>Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30368737">
<a name="30368737"></a>Gorelik E, Masarwa R, Perlman A, et al. Fluoroquinolones and cardiovascular risk: A systematic review, meta-analysis and network meta-analysis. <i>Drug Saf</i>. 2019;42(4):529‐538. doi:10.1007/s40264-018-0751-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30368737/pubmed" id="30368737" target="_blank">30368737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>J Antimicrob Chemother</i>. 2012;67(2):269-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3410603">
<a name="3410603"></a>Guay DRP, Awni WM, Peterson PK, et al. Single and Multiple Dose Pharmacokinetics of Oral Ciprofloxacin in Elderly Patients. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1988;26(6):279-284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/3410603/pubmed" id="3410603" target="_blank">3410603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11170940">
<a name="11170940"></a>Guerrant RL, Van Gilder T, Steiner TS, et al; Infectious Diseases Society of America. Practice guidelines for the management of infectious diarrhea. <i>Clin Infect Dis.</i> 2001;32(3):331-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11170940/pubmed" id="11170940" target="_blank">11170940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.1">
<a name="Hooton.1"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2">
<a name="Hooton.2"></a>Gupta K. Acute simple cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 16, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.3">
<a name="Hooton.3"></a>Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 11, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14576649">
<a name="14576649"></a>Hällgren J, Tengvall-Linder M, Persson M, Wahlgren CF. Stevens-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. <i>J Am Acad Dermatol</i>. 2003;49(5)(suppl):S267‐S269. doi:10.1016/s0190-9622(03)00478-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/14576649/pubmed" id="14576649" target="_blank">14576649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8390432">
<a name="8390432"></a>Halliwell RF, Davey PG, Lambert JJ. Antagonism of GABAA receptors by 4-quinolones. <i>J Antimicrob Chemother</i>. 1993;31(4):457‐462. doi:10.1093/jac/31.4.457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/8390432/pubmed" id="8390432" target="_blank">8390432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17950810">
<a name="17950810"></a>Hatzaras IS, Bible JE, Koullias GJ, Tranquilli M, Singh M, Elefteriades JA. Role of exertion or emotion as inciting events for acute aortic dissection. <i>Am J Cardiol</i>. 2007;100(9):1470‐1472. doi:10.1016/j.amjcard.2007.06.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/17950810/pubmed" id="17950810" target="_blank">17950810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1501036">
<a name="1501036"></a>Harmon T, Burkhart G, Applebaum H. Perforated Pseudomembranous Colitis in the Breast-Fed Infant. <i>J Pediatr Surg</i>. 1992;27(6):744-746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1501036/pubmed" id="1501036" target="_blank">1501036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26785402">
<a name="26785402"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med.</i> 2016;164(6):425-434. doi:10.7326/M15-1840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26785402/pubmed" id="26785402" target="_blank">26785402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16205075">
<a name="16205075"></a>Hausermann P, Scherer K, Weber M, Bircher AJ. Ciprofloxacin-induced acute generalized exanthematous pustulosis mimicking bullous drug eruption confirmed by a positive patch test. <i>Dermatology</i>. 2005;211(3):277-280. doi:10.1159/000087024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16205075/pubmed" id="16205075" target="_blank">16205075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8787869">
<a name="8787869"></a>Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. <i>Antimicrob Agents Chemother</i>. 1996;40(1):6-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/8787869/pubmed" id="8787869" target="_blank">8787869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19209277">
<a name="19209277"></a>Hedge DD, Strain JD, Heins JR, Farver DK. New advances in the treatment of Clostridium difficile infection (CDI). <i>Ther Clin Risk Manag</i>. 2008;4(5):949-964. doi:10.2147/tcrm.s3145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19209277/pubmed" id="19209277" target="_blank">19209277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577. doi:10.1592/phco.29.5.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8686718">
<a name="8686718"></a>Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. <i>Am J Med</i>. 1996;101(1):68-76. doi:10.1016/s0002-9343(96)00070-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/8686718/pubmed" id="8686718" target="_blank">8686718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24447897">
<a name="24447897"></a>Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis</i>. 2014;20(2):e130687. doi:10.3201/eid2002.130687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24447897/pubmed" id="24447897" target="_blank">24447897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hicks.1">
<a name="Hicks.1"></a>Hicks CB. Chancroid. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2230180">
<a name="2230180"></a>Hillman RJ, Rao GG, Harris JR, Taylor-Robinson D. Ciprofloxacin as a cause of <i>Clostridium difficile</i>-associated diarrhoea in an HIV antibody-positive patient. <i>J Infect</i>. 1990;21(2):205-7. doi:10.1016/0163-4453(90)91857-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2230180/pubmed" id="2230180" target="_blank">2230180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160669">
<a name="34160669"></a>Hirt D, Oualha M, Pasquiers B, et al. Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens. <i>Eur J Clin Pharmacol</i>. 2021;77(11):1687-1695. doi:10.1007/s00228-021-03174-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/34160669/pubmed" id="34160669" target="_blank">34160669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hohmann.1">
<a name="Hohmann.1"></a>Hohmann EL. Nontyphoidal Salmonella: Gastrointestinal infection and carriage. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hohmann.2">
<a name="Hohmann.2"></a>Hohmann EL. Nontyphoidal Salmonella bacteremia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 6, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1999905">
<a name="1999905"></a>Holley HP Jr. Successful treatment of cat-scratch disease with ciprofloxacin. <i>JAMA</i>. 1991;265(12):1563-1565.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1999905/pubmed" id="1999905" target="_blank">1999905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2670382">
<a name="2670382"></a>Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. <i>Clin Nephrol</i>. 1989;32(2):75-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2670382/pubmed" id="2670382" target="_blank">2670382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22318279">
<a name="22318279"></a>Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. <i>JAMA</i>. 2012;307(6):583-589. doi:10.1001/jama.2012.80<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22318279/pubmed" id="22318279" target="_blank">22318279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11850858">
<a name="11850858"></a>Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer. <i>Clin Infect Dis</i>. 2002;15;34(6):730-751.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11850858/pubmed" id="11850858" target="_blank">11850858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22752519">
<a name="22752519"></a>Humphries RM, Fang FC, Aarestrup FM, Hindler JA. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. <i>Clin Infect Dis</i>. 2012;55(8):1107-1113. doi:10.1093/cid/cis600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22752519/pubmed" id="22752519" target="_blank">22752519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32004540">
<a name="32004540"></a>Iguchi T, Goto K, Watanabe K, et al. Fluoroquinolones suppress gluconeogenesis by inhibiting fructose 1,6-bisphosphatase in primary monkey hepatocytes. <i>Toxicol In Vitro</i>. 2020;65:104786. doi:10.1016/j.tiv.2020.104786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/32004540/pubmed" id="32004540" target="_blank">32004540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25902267">
<a name="25902267"></a>Ilgin S, Can OD, Atli O, Ucel UI, Sener E, Guven I. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. <i>Toxicol Mech Methods</i>. 2015;25(5):374‐381. doi:10.3109/15376516.2015.1026008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/25902267/pubmed" id="25902267" target="_blank">25902267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29866687">
<a name="29866687"></a>Iliyas M, Ram Subba Reddy M, Devi U. Ciprofloxacin-induced generalised non-bullous fixed drug eruption. <i>BMJ Case Rep</i>. 2018;2018:bcr2018224858. Published June 4, 2018. doi:10.1136/bcr-2018-224858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29866687/pubmed" id="29866687" target="_blank">29866687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10807389">
<a name="10807389"></a>Inglesby TV, Dennis DT, Henderson DA, et al; Working Group on Civilian Biodefense. Plague as a biological weapon: medical and public health management. <i>JAMA</i>. 2000;283(17):2281-2290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10807389/pubmed" id="10807389" target="_blank">10807389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10328075">
<a name="10328075"></a>Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense. <i>JAMA.</i> 1999;281(18):1735-1745.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10328075/pubmed" id="10328075" target="_blank">10328075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IPGCipro.1">
<a name="IPGCipro.1"></a>IPG-Ciprofloxacin tablets [product monograph]. Ottawa, Ontario, Canada: Marcan Pharmaceuticals Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27940800">
<a name="27940800"></a>Jackson MA, Schutze GE; Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. <i>Pediatrics</i>. 2016;138(5):e20162706. doi:10.1542/peds.2016-2706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/27940800/pubmed" id="27940800" target="_blank">27940800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21879778">
<a name="21879778"></a>Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. <i>Drug Saf</i>. 2011;34(10):839‐847. doi:10.2165/11593110-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21879778/pubmed" id="21879778" target="_blank">21879778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21048525">
<a name="21048525"></a>Kaguelidou F, Turner MA, Choonara I, et al. Ciprofloxacin Use in Neonates: A Systematic Review of the Literature. <i>Pediatr Infect Dis J</i>. 2011;30(2):e29-e37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21048525/pubmed" id="21048525" target="_blank">21048525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23825301">
<a name="23825301"></a>Kalghatgi S, Spina CS, Costello JC, et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells. <i>Sci Transl Med</i>. 2013;5(192):192ra85. doi:10.1126/scitranslmed.3006055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23825301/pubmed" id="23825301" target="_blank">23825301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11125032">
<a name="11125032"></a>Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. <i>Mol Pharmacol</i>. 2001;59(1):122‐126. doi:10.1124/mol.59.1.122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11125032/pubmed" id="11125032" target="_blank">11125032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kapila.1">
<a name="Kapila.1"></a>Kapila K, Chysky V, Hullman R, et al. Worldwide Clinical Experience on Safety of Ciprofloxacin in Children on Compassionate Use Basis. <i>Proceedings of Third International Symposium on New Quinolones</i>. Vancouver, Canada; 1990, 9.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19578229">
<a name="19578229"></a>Kaushik JS, Gupta P, Faridi MM, Das S. Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. <i>Indian Pediatr</i>. 2010;47(4):309-315. doi:10.1007/s13312-010-0059-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19578229/pubmed" id="19578229" target="_blank">19578229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20399988">
<a name="20399988"></a>Kelesidis T, Fleisher J, Tsiodras S. Anaphylactoid reaction considered ciprofloxacin related: a case report and literature review. <i>Clin Ther</i>. 2010;32(3):515‐526. doi:10.1016/j.clinthera.2010.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/20399988/pubmed" id="20399988" target="_blank">20399988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10423465">
<a name="10423465"></a>Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. <i>N Engl J Med</i>. 1999;341(5):312-318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10423465/pubmed" id="10423465" target="_blank">10423465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23358983">
<a name="23358983"></a>Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV. <i>J Clin Oncol</i>. 2013;31(9):1149-1156. doi:10.1200/JCO.2012.45.8109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23358983/pubmed" id="23358983" target="_blank">23358983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766835">
<a name="12766835"></a>Khaliq Y, Zhanel GG. Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature. <i>Clin Infect Dis</i>. 2003;36(11):1404-1410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12766835/pubmed" id="12766835" target="_blank">12766835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8709688">
<a name="8709688"></a>Khan WA, Bennish ML, Seas C, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. <i>Lancet</i>. 1996;348(9023):296-300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/8709688/pubmed" id="8709688" target="_blank">8709688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30003982">
<a name="30003982"></a>Kim WB, Shelley AJ, Novice K, Joo J, Lim HW, Glassman SJ. Drug-induced phototoxicity: A systematic review. <i>J Am Acad Dermatol</i>. 2018;79(6):1069‐1075. doi:10.1016/j.jaad.2018.06.061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30003982/pubmed" id="30003982" target="_blank">30003982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9536423">
<a name="9536423"></a>Kimura M, Kawada A. Photosensitivity induced by lomefloxacin with cross-photosensitivity to ciprofloxacin and fleroxacin. <i>Contact Dermatitis</i>. 1998;38(3):180. doi:10.1111/j.1600-0536.1998.tb05698.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/9536423/pubmed" id="9536423" target="_blank">9536423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10529884">
<a name="10529884"></a>Krcméry V Jr, Filka J, Uher J, et al. Ciprofloxacin in Treatment of Nosocomial Meningitis in Neonates and in Infants: Report of 12 Cases and Review. <i>Diagn Microbiol Infect Dis</i>. 1999;35(1):75-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10529884/pubmed" id="10529884" target="_blank">10529884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21569745">
<a name="21569745"></a>Kulthanan K, Chularojanamontri L, Manapajon A, Dhana N, Jongjarearnprasert K. Cutaneous adverse reactions to fluoroquinolones. <i>Dermatitis</i>. 2011;22(3):155-160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21569745/pubmed" id="21569745" target="_blank">21569745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1283606">
<a name="1283606"></a>Kumar A, Hay MB, Maier GA, Dyke JW. Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for <i>Pseudomonas cepacia</i>. <i>J Antimicrob Chemother.</i> 1992;30(5):597-602. doi:10.1093/jac/30.5.597<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1283606/pubmed" id="1283606" target="_blank">1283606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2836821">
<a name="2836821"></a>LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. <i>Pharmacotherapy</i>. 1988;8(1):3-33. doi:10.1002/j.1875-9114.1988.tb04058.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2836821/pubmed" id="2836821" target="_blank">2836821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30213330">
<a name="30213330"></a>Lee CC, Lee MG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection. <i>J Am Coll Cardiol</i>. 2018;72(12):1369-1378. doi:10.1016/j.jacc.2018.06.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30213330/pubmed" id="30213330" target="_blank">30213330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11099086">
<a name="11099086"></a>Leibovitz E, Janco J, Piglansky L, et al. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. <i>Pediatr Infect Dis J</i>. 2000;19(11):1060-1067. doi:10.1097/00006454-200011000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11099086/pubmed" id="11099086" target="_blank">11099086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lewis.1">
<a name="Lewis.1"></a>Lewis SJ, Chaijamorn W, Shaw AR, Mueller BA. In silico trials using Monte Carlo simulation to evaluate ciprofloxacin and levofloxacin dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. <i>Ren Replace Ther.</i> 2016;2(1):45.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32617205">
<a name="32617205"></a>Liaqat A, Barlas A, Barlas T, Khurram H, Liaqat H. Ciprofloxacin-induced reaction imitating a lupus flare: a case report. <i>Cureus</i>. 2020;12(5):e8327. doi:10.7759/cureus.8327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/32617205/pubmed" id="32617205" target="_blank">32617205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol.</i> 2018;113(4):481-517. doi: 10.1038/ajg.2018.27. Erratum in: <i>Am J Gastroenterol.</i> 2018;113(7):1101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12911170">
<a name="12911170"></a>Lim S, Alam MG. Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia. <i>Ren Fail</i>. 2003;25(4):647‐651. doi:10.1081/jdi-120022557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12911170/pubmed" id="12911170" target="_blank">12911170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20397737">
<a name="20397737"></a>Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. <i>Drug Saf</i>. 2010;33(5):353‐369. doi:10.2165/11536360-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/20397737/pubmed" id="20397737" target="_blank">20397737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30856392">
<a name="30856392"></a>Liu R, Hu S, Zhang Y, et al. Mast cell-mediated hypersensitivity to fluoroquinolone is MRGPRX2 dependent. <i>Int Immunopharmacol</i>. 2019;70:417‐427. doi:10.1016/j.intimp.2019.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30856392/pubmed" id="30856392" target="_blank">30856392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9624471">
<a name="9624471"></a>Loebstein R, Addis A, Ho E, et al. Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter, Prospective Controlled Study. <i>Antimicrob Agents Chemother</i>. 1998;42(6):1336-1339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/9624471/pubmed" id="9624471" target="_blank">9624471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1763542">
<a name="1763542"></a>Lomaestro BM, Bailie GR. Quinolone-Cation Interactions: A Review. <i>DICP</i>. 1991;25(11):1249-1258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1763542/pubmed" id="1763542" target="_blank">1763542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19250986">
<a name="19250986"></a>Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2009;7(4):487-493. doi:10.1016/j.cgh.2008.12.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19250986/pubmed" id="19250986" target="_blank">19250986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9120330">
<a name="9120330"></a>Ludlam H, Wreghitt TG, Thornton S, et al. Q Fever in Pregnancy. <i>J Infect</i>. 34(1):75-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/9120330/pubmed" id="9120330" target="_blank">9120330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32702756">
<a name="32702756"></a>Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. <i>Blood</i>. 2020;136(11):1225-1240. doi:10.1182/blood.2019000944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/32702756/pubmed" id="32702756" target="_blank">32702756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7621639">
<a name="7621639"></a>Mackay AD, Mehta A. Autoimmune Haemolytic Anemia Associated With Ciprofloxacin. <i>Clin Lab Haematol</i>. 1995;17(1):97-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/7621639/pubmed" id="7621639" target="_blank">7621639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30658060">
<a name="30658060"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD parenthood project working group. <i>Gastroenterology</i>. 2019;156(5):1508-1524. doi:10.1053/j.gastro.2018.12.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30658060/pubmed" id="30658060" target="_blank">30658060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11557500">
<a name="11557500"></a>Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients. <i>Antimicrob Agents Chemother</i>. 2001;45(10):2949-2954.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11557500/pubmed" id="11557500" target="_blank">11557500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14713922">
<a name="14713922"></a>Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. <i>J Allergy Clin Immunol</i>. 2004;113(1):155‐160. doi:10.1016/j.jaci.2003.09.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/14713922/pubmed" id="14713922" target="_blank">14713922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1608685">
<a name="1608685"></a>Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. <i>Pediatr Infect Dis J</i>. 1992;11(6):474-478.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1608685/pubmed" id="1608685" target="_blank">1608685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25450476">
<a name="25450476"></a>Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. <i>Clin Ther</i>. 2014;36(11):1489‐1511.e4. doi:10.1016/j.clinthera.2014.09.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/25450476/pubmed" id="25450476" target="_blank">25450476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for <i>Clostridium difficile</i> Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24457117">
<a name="24457117"></a>Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24457117/pubmed" id="24457117" target="_blank">24457117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987142">
<a name="29987142"></a>Meesters K, Michelet R, Mauel R, et al. Results of a multicenter population pharmacokinetic study of ciprofloxacin in children with complicated urinary tract infection. <i>Antimicrob Agents Chemother</i>. 2018;62(9):e00517-18. doi:10.1128/AAC.00517-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29987142/pubmed" id="29987142" target="_blank">29987142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30809871">
<a name="30809871"></a>Meng L, Huang J, Jia Y, Huang H, Qiu F, Sun S. Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system. <i>Int J Clin Pract</i>. 2019;73(5):e13331. doi:10.1111/ijcp.13331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30809871/pubmed" id="30809871" target="_blank">30809871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyrier.1">
<a name="Meyrier.1"></a>Meyrier A, Fekete T. Acute bacterial prostatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyrier.2">
<a name="Meyrier.2"></a>Meyrier A, Fekete T. Chronic bacterial prostatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21483143">
<a name="21483143"></a>Milanlioglu A, Torlak PT. Intracranial hypertension and ciprofloxacin. <i>Neurol India</i>. 2011;59(2):302‐303. doi:10.4103/0028-3886.79158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21483143/pubmed" id="21483143" target="_blank">21483143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9840238">
<a name="9840238"></a>Mimoz O, Binter V, Jacolot A, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. <i>Intensive Care Med</i>. 1998;24(10):1047-1051. doi:10.1007/s001340050714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/9840238/pubmed" id="9840238" target="_blank">9840238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31135195">
<a name="31135195"></a>Mollica AJ, Mollica AJ, Grant E, Malik A, Claydon M. Ciprofloxacin-Induced Bullae of the Lower Extremity: A Case of a Fixed Drug Reaction. <i>J Am Podiatr Med Assoc</i>. 2019;109(2):155‐158. doi:10.7547/17-088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31135195/pubmed" id="31135195" target="_blank">31135195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2258353">
<a name="2258353"></a>Montay G, Gaillot J. Pharmacokinetics of fluoroquinolones in hepatic failure. <i>J Antimicrob Chemother</i>. 1990;26 Suppl B:61-67. doi:10.1093/jac/26.suppl_b.61<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2258353/pubmed" id="2258353" target="_blank">2258353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31034074">
<a name="31034074"></a>Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X. Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy. <i>JAMA Neurol</i>. 2019;76(7):827‐833. doi:10.1001/jamaneurol.2019.0887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31034074/pubmed" id="31034074" target="_blank">31034074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28070469">
<a name="28070469"></a>Morgado B, Madeira C, Pinto J, Pestana J. Leukocytoclastic vasculitis with systemic involvement associated with ciprofloxacin therapy: case report and review of the literature. <i>Cureus</i>. 2016;8(11):e900. doi:10.7759/cureus.900<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28070469/pubmed" id="28070469" target="_blank">28070469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2347665">
<a name="2347665"></a>Mrhar A, Karba R, Drinovec J, et al. Computer simulation of ciprofloxacin pharmacokinetics in patients on CAPD. <i>Int J Artif Organs</i>. 1990;13(3):169-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2347665/pubmed" id="2347665" target="_blank">2347665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2224281">
<a name="2224281"></a>Mumford CJ, Ginsberg L. Ciprofloxacin and myasthenia gravis. <i>BMJ</i>. 1990;301(6755):818. doi:10.1136/bmj.301.6755.818-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2224281/pubmed" id="2224281" target="_blank">2224281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25949980">
<a name="25949980"></a>Nair PA. Ciprofloxacin induced bullous fixed drug reaction: three case reports. <i>J Family Med Prim Care</i>. 2015;4(2):269‐272. doi:10.4103/2249-4863.154673<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/25949980/pubmed" id="25949980" target="_blank">25949980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19817675">
<a name="19817675"></a>Navaneethan U, Shen B. Pros and cons of antibiotic therapy for pouchitis. <i>Expert Rev Gastroenterol Hepatol</i>. 2009;3(5):547-559. doi:10.1586/egh.09.37<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19817675/pubmed" id="19817675" target="_blank">19817675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS; contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep</i>. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31785173">
<a name="31785173"></a>Nguyen N, Zhang B, Holubar SD, Pardi DS, Singh S. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. <i>Cochrane Database Syst Rev</i>. 2019;11(11):CD001176. doi:10.1002/14651858.CD001176.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31785173/pubmed" id="31785173" target="_blank">31785173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34588142">
<a name="34588142"></a>Nicholson TT, Smith A, McKone EF, Gallagher CG. Duration of intravenous antibiotic treatment for acute exacerbations of cystic fibrosis: A systematic review. <i>J Cyst Fibros</i>. 2022;21(4):562-573. doi:10.1016/j.jcf.2021.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/34588142/pubmed" id="34588142" target="_blank">34588142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1794020">
<a name="1794020"></a>Nilsson-Ehle I, Ljungberg B. Quinolone Disposition in the Elderly: Practical Implications. <i>Drugs Aging</i>. 1991;1(4):279-288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1794020/pubmed" id="1794020" target="_blank">1794020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3555029">
<a name="3555029"></a>Nix DE, Cumbo TJ, Kuritzky P, DeVito JM, Schentag JJ. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. <i>Am J Med</i>. 1987;82(4A):146-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/3555029/pubmed" id="3555029" target="_blank">3555029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12709719">
<a name="12709719"></a>Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. <i>Clin Pharmacol Ther</i>. 2003;73(4):292-303. doi:10.1016/s0009-9236(03)00009-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12709719/pubmed" id="12709719" target="_blank">12709719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20536364">
<a name="20536364"></a>Nouira S, Marghli S, Besbes L, et al. Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. <i>Clin Infect Dis.</i> 2010;51(2):143-149. doi:10.1086/653527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/20536364/pubmed" id="20536364" target="_blank">20536364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10692119">
<a name="10692119"></a>Ohshima A, Seo N, Takigawa M, Tokura Y. Formation of antigenic quinolone photoadducts on Langerhans cells initiates photoallergy to systemically administered quinolone in mice. <i>J Invest Dermatol</i>. 2000;114(3):569‐575. doi:10.1046/j.1523-1747.2000.00918.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10692119/pubmed" id="10692119" target="_blank">10692119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21356330">
<a name="21356330"></a>Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. <i>Clin Gastroenterol Hepatol</i>. 2011;9(6):517‐523.e3. doi:10.1016/j.cgh.2011.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21356330/pubmed" id="21356330" target="_blank">21356330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guideline by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2013;56(1):e1-e25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmon.1">
<a name="Osmon.1"></a>Osmon DR, Tande AJ. Osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30401472">
<a name="30401472"></a>Ouni B, Fathallah N, Slim R, Brahim A, Ben Salem C. Anaphylactic shock secondary to oral ofloxacin administration with cross-reactivity to levofloxacin and ciprofloxacin. <i>Therapie</i>. 2018;73(6):555-556. doi:10.1016/j.therap.2018.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30401472/pubmed" id="30401472" target="_blank">30401472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29519881">
<a name="29519881"></a>Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. <i>BMJ</i>. 2018;360:k678. doi:10.1136/bmj.k678<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29519881/pubmed" id="29519881" target="_blank">29519881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26865283">
<a name="26865283"></a>Patel K, Goldman JL. Safety concerns surrounding quinolone use in children. <i>J Clin Pharmacol</i>. 2016;56(9):1060-1075. doi:10.1002/jcph.715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26865283/pubmed" id="26865283" target="_blank">26865283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paul.1">
<a name="Paul.1"></a>Paul J, Brown NM. Tinnitus and Ciprofloxacin. <i>BMJ</i>. 1995;311(6999):232.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9521952">
<a name="9521952"></a>Peltola H, Ukkonen P, Saxen H, Staβ H. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children. <i>Pediatrics</i>. 1998;101(4, pt 1):658-662. doi:10.1542/peds.101.4.658<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/9521952/pubmed" id="9521952" target="_blank">9521952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.1">
<a name="Pemberton.1"></a>Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2658581">
<a name="2658581"></a>Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. <i>Am J Med</i>. 1989;86(6, pt 2):801-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2658581/pubmed" id="2658581" target="_blank">2658581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29928218">
<a name="29928218"></a>Popescu C. Severe acute axonal neuropathy induced by ciprofloxacin: A case report. <i>Case Rep Neurol</i>. 2018;10(2):124‐129. doi:10.1159/000489303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29928218/pubmed" id="29928218" target="_blank">29928218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31029713">
<a name="31029713"></a>Porta L, Lee MG, Hsu WT, Hsu TC, Tsai TY, Lee CC. Fluoroquinolone use and serious arrhythmias: A nationwide case-crossover study. <i>Resuscitation</i>. 2019;139:262-268. doi:10.1016/j.resuscitation.2019.04.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31029713/pubmed" id="31029713" target="_blank">31029713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30266895">
<a name="30266895"></a>Radovanovic M, Dushenkovska T, Cvorovic I, et al. Idiosyncratic Drug-Induced Liver Injury Due to Ciprofloxacin: A Report of Two Cases and Review of the Literature. <i>Am J Case Rep</i>. 2018;19:1152-1161. doi:10.12659/AJCR.911393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30266895/pubmed" id="30266895" target="_blank">30266895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27068718">
<a name="27068718"></a>Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol</i>. 2016;111(5):602-622. doi:10.1038/ajg.2016.126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/27068718/pubmed" id="27068718" target="_blank">27068718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30809648">
<a name="30809648"></a>Roberts JA, Alobaid AS, Wallis SC, Perner A, Lipman J, Sjövall F. Defining optimal dosing of ciprofloxacin in patients with septic shock. <i>J Antimicrob Chemother</i>. 2019;74(6):1662-1669. doi:10.1093/jac/dkz069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30809648/pubmed" id="30809648" target="_blank">30809648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26957490">
<a name="26957490"></a>Roger C, Wallis SC, Louart B, et al. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. <i>J Antimicrob Chemother</i>. 2016;71(6):1643-1650. doi:10.1093/jac/dkw043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26957490/pubmed" id="26957490" target="_blank">26957490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7557868">
<a name="7557868"></a>Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. <i>Hepatology</i>. 1995;22(4, pt 1):1171-1174. doi:10.1016/0270-9139(95)90626-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/7557868 /pubmed" id="7557868 " target="_blank">7557868 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25833927">
<a name="25833927"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis executive summary. <i>Otolaryngol Head Neck Surg</i>. 2015;152(4):598-609. doi:10.1177/0194599815574247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/25833927/pubmed" id="25833927" target="_blank">25833927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9002120">
<a name="9002120"></a>Rubio TT, Miles MV, Lettieri JT, et al. Pharmacokinetic Disposition of Sequential Intravenous/Oral Ciprofloxacin in Pediatric Cystic Fibrosis Patients With Acute Pulmonary Exacerbation. <i>Pediatr Infect Dis J</i>. 1997;16:112-117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/9002120/pubmed" id="9002120" target="_blank">9002120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2292201">
<a name="2292201"></a>Ruhnke M, Trautmann M, Borner K, Hopfenmüller W. Pharmacokinetics of ciprofloxacin in liver cirrhosis. <i>Chemotherapy</i>. 1990;36(6):385-391. doi:10.1159/000238793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2292201/pubmed" id="2292201" target="_blank">2292201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.1">
<a name="Runyon.1"></a>Runyon BA. Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16760445">
<a name="16760445"></a>Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. <i>N Engl J Med</i>. 2006;354(23):2452-2462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16760445/pubmed" id="16760445" target="_blank">16760445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16182896">
<a name="16182896"></a>Saha D, Khan WA, Karim MM, Chowdhury HR, Salam MA, Bennish ML. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. <i>Lancet</i>. 2005;366(9491):1085-1093. doi:10.1016/S0140-6736(05)67290-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16182896/pubmed" id="16182896" target="_blank">16182896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32525203">
<a name="32525203"></a>Same RG, Amoah J, Hsu AJ, et al. The association of antibiotic duration with successful treatment of community-acquired pneumonia in children. <i>J Pediatric Infect Dis Soc</i>. 2021;10(3):267-273. doi:10.1093/jpids/piaa055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/32525203/pubmed" id="32525203" target="_blank">32525203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30385582">
<a name="30385582"></a>Same RG, Tamma PD. <i>Campylobacter</i> infections in children. <i>Pediatr Rev</i>. 2018;39(11):533-541. doi:10.1542/pir.2017-0285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30385582/pubmed" id="30385582" target="_blank">30385582</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sandoz Ciprofloxacin (ciprofloxacin) tablets and intravenous infusion [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8320021">
<a name="8320021"></a>Scheife RT, Cramer WR, Decker EL. Photosensitizing potential of ofloxacin. <i>Int J Dermatol</i>. 1993;32(6):413‐416. doi:10.1111/j.1365-4362.1993.tb02810.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/8320021/pubmed" id="8320021" target="_blank">8320021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16393267">
<a name="16393267"></a>Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. <i>Clin Exp Allergy</i>. 2006;36(1):59‐69. doi:10.1111/j.1365-2222.2006.02402.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16393267/pubmed" id="16393267" target="_blank">16393267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879279">
<a name="23879279"></a>Sedlak T, Shufelt C, Iribarren C, et al. Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval. <i>Ann Noninvasive Electrocardiol</i>. 2013;18(4):389-398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23879279/pubmed" id="23879279" target="_blank">23879279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034766">
<a name="20034766"></a>Sendzik J, Shakibaei M, Schäfer-Korting M, Lode H, Stahlmann R. Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. Int J Antimicrob Agents. 2010;35(4):366‐374. doi:10.1016/j.ijantimicag.2009.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/20034766/pubmed" id="20034766" target="_blank">20034766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15890441">
<a name="15890441"></a>Sendzik J, Shakibaei M, Schäfer-Korting M, Stahlmann R. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. <i>Toxicology</i>. 2005;212(1):24‐36. doi:10.1016/j.tox.2005.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15890441/pubmed" id="15890441" target="_blank">15890441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.1">
<a name="Sethi.1"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28719679">
<a name="28719679"></a>Shah SD, Cifu AS. Management of acute diverticulitis. <i>JAMA</i>. 2017;318(3):291-292. doi:10.1001/jama.2017.6373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28719679/pubmed" id="28719679" target="_blank">28719679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis. </i>2017;65(12):e45-e80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11720319">
<a name="11720319"></a>Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. <i>Inflamm Bowel Dis</i>. 2001;7(4):301-305. doi:10.1097/00054725-200111000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11720319/pubmed" id="11720319" target="_blank">11720319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shen.2020">
<a name="Shen.2020"></a>Shen B. Management of acute and chronic pouchitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 2, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165476">
<a name="30165476"></a>Shin JY, Jeong S, Jeon HL, et al. The risk profile of rhegmatogenous retinal detachment before and after using a fluoroquinolone: a 12 year nationwide self-controlled case series study. <i>J Antimicrob Chemother</i>. 2018;73(12):3442‐3453. doi:10.1093/jac/dky336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/30165476/pubmed" id="30165476" target="_blank">30165476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28791716">
<a name="28791716"></a>Sim DW, Yu JE, Jeong J, Koh YI. Ciprofloxacin-induced immune-mediated thrombocytopenia: No cross-reactivity with gemifloxacin. <i>J Clin Pharm Ther</i>. 2018;43(1):134-136. doi:10.1111/jcpt.12596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28791716/pubmed" id="28791716" target="_blank">28791716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28739200">
<a name="28739200"></a>Singh S, Nautiyal A. Aortic Dissection and Aortic Aneurysms Associated with Fluoroquinolones: A Systematic Review and Meta-Analysis. Am J Med. 2017;130(12):1449‐1457.e9. doi:10.1016/j.amjmed.2017.06.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28739200/pubmed" id="28739200" target="_blank">28739200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2360826">
<a name="2360826"></a>Slama TG. Serum sickness-like illness associated with ciprofloxacin. <i>Antimicrob Agents Chemother</i>. 1990;34(5):904‐905. doi:10.1128/aac.34.5.904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2360826/pubmed" id="2360826" target="_blank">2360826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>. 2010;50(12):1695]. <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.2019">
<a name="Spach.2019"></a>Spach DH, Kaplan SL. Treatment of cat scratch disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21816053">
<a name="21816053"></a>Spooner AM, Deegan C, D'Arcy DM, Gowing CM, Donnelly MB, Corrigan OI. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. <i>BMC Clin Pharmacol</i>. 2011;11:11. doi: 10.1186/1472-6904-11-11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21816053/pubmed" id="21816053" target="_blank">21816053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28063266">
<a name="28063266"></a>Stefano GB, Samuel J, Kream RM. Antibiotics May Trigger Mitochondrial Dysfunction Inducing Psychiatric Disorders. <i>Med Sci Monit</i>. 2017;23:101-106. Published 2017 Jan 7. doi:10.12659/msm.899478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28063266/pubmed" id="28063266" target="_blank">28063266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14738249">
<a name="14738249"></a>Steiger D, Bubendorf L, Oberholzer M, Tamm M, Leuppi JD. Ciprofloxacin-induced acute interstitial pneumonitis. <i>Eur Respir J</i>. 2004;23(1):172‐174. doi:10.1183/09031936.03.00057903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/14738249/pubmed" id="14738249" target="_blank">14738249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25477258">
<a name="25477258"></a>Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. <i>Eur Urol</i>. 2015;67(3):546-558. doi:10.1016/j.eururo.2014.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/25477258/pubmed" id="25477258" target="_blank">25477258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>. 2015;60(9):1448]. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22949224">
<a name="22949224"></a>Stockmann C, Sherwin CM, Zobell JT, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. <i>Pediatr Pulmonol</i>. 2013;48(3):211-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22949224/pubmed" id="22949224" target="_blank">22949224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26453777">
<a name="26453777"></a>Stollman N, Smalley W, Hirano I; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of acute diverticulitis. <i>Gastroenterology</i>. 2015;149(7):1944-1949. doi:10.1053/j.gastro.2015.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26453777/pubmed" id="26453777" target="_blank">26453777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stout.1">
<a name="Stout.1"></a>Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24827622">
<a name="24827622"></a>Sung HY, Kim JI, Lee HJ, et al. Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis. <i>Gut Liver</i>. 2014;8(3):265-270. doi:10.5009/gnl.2014.8.3.265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24827622/pubmed" id="24827622" target="_blank">24827622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26400582">
<a name="26400582"></a>Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: A systematic review. <i>Neurology</i>. 2015;85(15):1332-1341. doi:10.1212/WNL.0000000000002023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26400582/pubmed" id="26400582" target="_blank">26400582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28360365">
<a name="28360365"></a>Szeto CC, Li PK, Johnson DW, et al. ISPD catheter-related infection recommendations: 2017 update. <i>Perit Dial Int</i>. 2017;37(2):141-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28360365/pubmed" id="28360365" target="_blank">28360365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes. <i>Am J Clin Dermatol</i>. 2020;21(2):163‐172. doi:10.1007/s40257-019-00485-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29702230">
<a name="29702230"></a>Tandan M, Cormican M, Vellinga A. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled trials. <i>Int J Antimicrob Agents</i>. 2018;52(5):529‐540. doi:10.1016/j.ijantimicag.2018.04.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29702230/pubmed" id="29702230" target="_blank">29702230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29461916">
<a name="29461916"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. <i>J Clin Oncol</i>. 2018;36(14):1443-1453. doi:10.1200/JCO.2017.77.6211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29461916/pubmed" id="29461916" target="_blank">29461916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31341415">
<a name="31341415"></a>Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: A pharmacovigilance study of the FDA adverse event reporting system. <i>Int J Med Sci</i>. 2019;16(7):1018‐1022. doi:10.7150/ijms.34141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31341415/pubmed" id="31341415" target="_blank">31341415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18316137">
<a name="18316137"></a>Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. <i>J Hepatol</i>. 2008;48(5):774-779. doi:10.1016/j.jhep.2008.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/18316137 /pubmed" id="18316137 " target="_blank">18316137 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22971191">
<a name="22971191"></a>Tolland JP, Murphy BP, Boyle J, Hall V, McKenna KE, Elborn JS. Ciprofloxacin-induced phototoxicity in an adult cystic fibrosis population. <i>Photodermatol Photoimmunol Photomed</i>. 2012;28(5):258‐260. doi:10.1111/j.1600-0781.2012.00676.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22971191/pubmed" id="22971191" target="_blank">22971191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21585220">
<a name="21585220"></a>Tomé AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. <i>Drug Saf</i>. 2011;34(6):465‐488. doi:10.2165/11587280-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21585220/pubmed" id="21585220" target="_blank">21585220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22035890">
<a name="22035890"></a>Tsai WC, Yang YM. Fluoroquinolone-associated tendinopathy. <i>Chang Gung Med J</i>. 2011;34(5):461‐467.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22035890/pubmed" id="22035890" target="_blank">22035890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi: 10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12685882">
<a name="12685882"></a>Ulleryd P, Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. <i>Scand J Infect Dis</i>. 2003;35(1):34-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12685882/pubmed" id="12685882" target="_blank">12685882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10435684">
<a name="10435684"></a>Umut S, Tutluoglu B, Aydin Tosun G, et al. Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. Turkish Thoracic Society COPD Working Group. <i>J Chemother.</i> 1999;11(3):211-214. doi:10.1179/joc.1999.11.3.211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10435684/pubmed" id="10435684" target="_blank">10435684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Updated September 28, 2022. Accessed October 26, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.5">
<a name="HHS.5"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Children With and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines</a>. Updated September 2, 2022. Accessed October 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>US Food and Drug Administration. FDA drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. <a href="https://www.fda.gov/Drugs/DrugSafety/ucm500143.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm500143.htm</a>. Published May 12, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2292168">
<a name="2292168"></a>Vance-Bryan K, Guay DR, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. <i>Clin Pharmacokinet</i>. 1990;19(6):434-461. doi:10.2165/00003088-199019060-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2292168/pubmed" id="2292168" target="_blank">2292168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12039823">
<a name="12039823"></a>van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. <i>BMJ</i>. 2002;324(7349):1306‐1307. doi:10.1136/bmj.324.7349.1306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12039823/pubmed" id="12039823" target="_blank">12039823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27139161">
<a name="27139161"></a>VanDevanter DR, Flume PA, Morris N, Konstan MW. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. <i>J Cyst Fibros</i>. 2016;15(6):783-790. doi:10.1016/j.jcf.2016.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/27139161/pubmed" id="27139161" target="_blank">27139161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073652">
<a name="32073652"></a>van Dijk ST, Chabok A, Dijkgraaf MG, Boermeester MA, Smedh K. Observational versus antibiotic treatment for uncomplicated diverticulitis: an individual-patient data meta-analysis. <i>Br J Surg.</i> 2020;107(8):1062-1069. doi:10.1002/bjs.11465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/32073652/pubmed" id="32073652" target="_blank">32073652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28975050">
<a name="28975050"></a>van Samkar A, De Kleermaeker FGCM, Te Riele MGE, Verrips A. Negative myoclonus induced by ciprofloxacin. <i>Tremor Other Hyperkinet Mov (N Y)</i>. 2017;7:500. doi:10.7916/D8QC0FXT<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28975050/pubmed" id="28975050" target="_blank">28975050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21829747">
<a name="21829747"></a>Vinh H, Anh VT, Anh ND, et al. A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. <i>PLoS Negl Trop Dis</i>. 2011;5(8):e1264. doi:10.1371/journal.pntd.0001264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21829747/pubmed" id="21829747" target="_blank">21829747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.1">
<a name="Vollmer.1"></a>Vollmer CM, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21775695">
<a name="21775695"></a>Wall GC, Schirmer LL, Anliker LE, Tigges AE. Pharmacotherapy for acute pouchitis. <i>Ann Pharmacother</i>. 2011;45(9):1127-1137. doi:10.1345/aph.1P790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21775695/pubmed" id="21775695" target="_blank">21775695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11398692">
<a name="11398692"></a>Wallis SC, Mullany DV, Lipman J, Rickard CM, Daley PJ. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. <i>Intensive Care Med</i>. 2001;27(4):665-672. doi: 10.1007/s001340100857<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11398692/pubmed" id="11398692" target="_blank">11398692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;32(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the Risk Factors for Hospital-Onset <i>Clostridium difficile</i> Infections in a Large Healthcare System. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22911645">
<a name="22911645"></a>Weber IB, Turabelidze G, Patrick S, Griffith KS, Kugeler KJ, Mead PS. Clinical recognition and management of tularemia in Missouri: a retrospective records review of 121 cases. <i>Clin Infect Dis</i>. 2012;55(10):1283-1290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22911645/pubmed" id="22911645" target="_blank">22911645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.1">
<a name="Weintrob.1"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 17, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12749509">
<a name="12749509"></a>West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. <i>Clin Ther</i>. 2003;25(2):485-506. doi:10.1016/s0149-2918(03)80091-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12749509/pubmed" id="12749509" target="_blank">12749509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29790845">
<a name="29790845"></a>Williams PCM, Berkley JA. Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence. <i>Paediatr Int Child Health</i>. 2018;38(sup1):S50-S65. doi:10.1080/20469047.2017.1409454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29790845/pubmed" id="29790845" target="_blank">29790845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilson.1">
<a name="Wilson.1"></a>Wilson KH. Prevention of anthrax. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.1">
<a name="Wingard.1"></a>Wingard RJ. Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Acute diarrhea in adults and children: a global perspective. 2012. http://www.worldgastroenterology.org/guidelines/global-guidelines/acute-diarrhea/acute-diarrhea-english 
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO); UNICEF. Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO). Guidelines for the Control of Shigellosis, Including Epidemics Due to <i>Shigella dysenteriae</i> type 1. 2005. http://whqlibdoc.who.int/publications/2005/9241592330.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.4">
<a name="WHO.4"></a>World Health Organization (WHO). WHO guidelines on tularaemia. 2007. <a href="https://www.cdc.gov/tularemia/resources/whotularemiamanual.pdf%20" target="_blank">http://www.cdc.gov/tularemia/resources/whotularemiamanual.pdf </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.5">
<a name="WHO.5"></a>World Health Organization (WHO). Guidelines for the management of symptomatic sexually transmitted infections. Published June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24223408">
<a name="24223408"></a>Yoon BI, Han DS, Ha US, et al. Clinical courses following acute bacterial prostatitis. <i>Prostate Int</i>. 2013;1(2):89-93. doi:10.12954/PI.12013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24223408/pubmed" id="24223408" target="_blank">24223408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35747047">
<a name="35747047"></a>Yousafzai ZA, Amin QK, Qayyum W, Saeed A, Anthony N. Ciprofloxacin-induced acute delirium in a young female. <i>Cureus</i>. 2022;14(5):e25182. doi:10.7759/cureus.25182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/35747047/pubmed" id="35747047" target="_blank">35747047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31077091">
<a name="31077091"></a>Yu X, Jiang DS, Wang J, et al. Fluoroquinolone use and the risk of collagen-associated adverse events: A systematic review and meta-analysis. <i>Drug Saf</i>. 2019;42(9):1025‐1033. doi:10.1007/s40264-019-00828-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/31077091/pubmed" id="31077091" target="_blank">31077091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15252190">
<a name="15252190"></a>Zacher JL, Givone DM. False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use. <i>Ann Pharmacother</i>. 2004;38:1525-1528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15252190/pubmed" id="15252190" target="_blank">15252190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25155587">
<a name="25155587"></a>Zhao W, Hill H, Le Guellec C, et al. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. <i>Antimicrob Agents Chemother</i>. 2014;58(11):6572-6580. doi:10.1128/AAC.03568-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/25155587/pubmed" id="25155587" target="_blank">25155587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9605897">
<a name="9605897"></a>Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. <i>JAMA</i>. 1998;279(19):1537-1541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/9605897/pubmed" id="9605897" target="_blank">9605897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35052907">
<a name="35052907"></a>Zoratti C, Moretti R, Rebuzzi L, et al. Antibiotics and liver cirrhosis: what the physicians need to know. <i>Antibiotics (Basel)</i>. 2021;11(1):31. doi:10.3390/antibiotics11010031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/35052907/pubmed" id="35052907" target="_blank">35052907</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9053 Version 836.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
